All Projects

A

Abaloparatide-SC for the Treatment of Post-menopausal Osteoporosis

Abaloparatide-SC is an injectable formulation of abaloparatide developed by Radius Health for the treatment of osteoporosis in post-menopausal women.

Abatacept (Orencia) – Treatment for Rheumatoid Arthritis (RA)

Abatacept (Orencia) was developed by Bristol-Myers-Squibb for the treatment of rheumatoid arthritis (RA). It is a biologic drug which contains a selective co-stimulation modulator.

Abecma (idecabtagene vicleucel) for the Treatment of Multiple Myeloma

Abecma (idecabtagene vicleucel) is the first approved CAR T-cell immunotherapy for relapsed or refractory (r/r) multiple myeloma.

Abilify (aripiprazole) Digital Medicine for Treatment of Schizophrenia

Abilify (aripiprazole), an orally administered dopamine partial agonist and a seratonin antagonist, was approved by US Food and Drug Administration (FDA) in November 2002 for the treatment of schizophrenia.

Abraxane for the Treatment of Late-Stage Pancreatic Cancer

Abraxane (albumin-bound paclitaxel for injectable suspension) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer.

ACE-031 for the Treatment of Duchenne Muscular Dystrophy

ACE-031 is an investigational protein therapeutic that is being developed by Acceleron Pharma for the treatment of Du

Acomplia (Rimonabant) – Investigational Agent for the Management of Obesity

Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for

Actemra – Biological Therapy for Rheumatoid Arthritis

Roche Pharmaceuticals' Actemra (tocilizumab) was approved as a rheumatoid arthritis treatment in the EU in January 2009

Actonel (Risedronate Sodium) – Treatment for Osteoporosis

Actonel is targeted for the treatment of osteoporosis in postmenopausal women. It is also indicated for the treatment of osteoporosis in men, to improve BMD and Paget's disease.

Adcetris (brentuximab vedotin) for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma

Adcetris® (brentuximab vedotin) is a treatment for relapsed or refractory (r/r) Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL).

Adempas (Riociguat) for Treatment of Pulmonary Hypertension

Adempas (riociguat) is indicated for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

Adlyxin (lixisenatide) for the Treatment of Type 2 Diabetes

Adlyxin (lixisenatide) is an injectable solution developed by Sanofi for the treatment of type 2 diabetes in adults.

Admelog (insulin lispro) for the Treatment of Type 1 and Type 2 Diabetes

Admelog® (insulin lispro) is a rapid-acting human insulin analogue approved as a follow-on product to treat type 1 and type 2 diabetes in adults and paediatric patients aged three years and older.

ADUHELM (aducanumab-avwa) for the Treatment of Alzheimer’s Disease

ADUHELM™ (aducanumab-avwa) is a first-of-its-kind monoclonal antibody indicated for the treatment of Alzheimer’s disease.

ADYNOVI for the Treatment of Adults and Adolescents with Haemophilia A

ADYNOVI® is an intravenous infusion indicated for the treatment of adults and adolescents with haemophilia A.

Afamelanotide, Photo-Protective Drug

Afamelanotide is a photo-protective drug that increases melanin levels in the human skin to gain protection from ultraviolet radiation (UVR) and sunlight.

Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures

Afinitor Disperz® (everolimus) is indicated for the treatment of tuberous sclerosis complex (TSC) associated partial-onset seizures in adult and paediatric patients.

Afluria Quadrivalent for Prevention of Infection from Influenza Virus

Afluria Quadrivalent is an inactivated influenza vaccine developed by Seqirus, which is developed to provide active immunisation against the disease.

Afrezza: Mealtime Insulin Therapy for Diabetes

Afrezza is a rapid-acting insulin therapy indicated for controlling hyperglycaemia in adult patients with type 1 and type 2 diabetes mellitus.

Aimovig (erenumab) for the Treatment of Episodic Migraine

Aimovig™ (erenumab) is the first CGRP inhibitor approved for preventive treatment of migraine in adults.

Alecensa (alectinib) for the Treatment of ALK-positive Non-small Cell Lung Cancer (NSCLC)

Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Alemtuzumab – Potential in Multiple Sclerosis (MS)

Alemtuzumab (marketed as Campath/MabCampath/Lemtrada) is an anti-CD52 monoclonal antibody (MAb) for which Bayer HealthCare holds exclusive global marketing rights. It was licensed in 2001 for the treatment of chronic lymphocytic leukaemia.

Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma

Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).

Almorexant for Treatment of Primary Insomnia

Almorexant is the first member of a new class of drugs called orexin receptor antagonists indicated for the treatment of

Alofisel (darvadstrocel) for the Treatment of Complex Perianal Fistulas in Crohn’s Disease

Alofisel® (formerly Cx601 / darvadstrocel) is the first allogeneic stem cell therapy to be approved for the treatment of complex perianal fistulas in adult patients with Crohn’s disease.

Alprolix for the Treatment of Haemophilia B

Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an intravenous injection indicated for the control and prevention of bleeding episodes, as well as routine prophylaxis in haemophilia B-affected adults and children aged 12 and above.

Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).

AM103 Experimental Treatment for Respiratory Diseases

Under development by Amira Pharmaceuticals, AM103 is a novel inhibitor of 5-lipoxygenase activating protein (FLAP) that

Amglidia (glibenclamide) for the Treatment of Neonatal Diabetes

Amglidia is a hybrid medicine indicated for the treatment of neonatal diabetes mellitus in newborns, infants, and children.

Amondys 45 (Casimersen) for the Treatment of Duchenne Muscular Dystrophy

Amondys 45 (casimersen) injection is an antisense oligonucleotide indicated for the treatment of patients with Duchenne muscular dystrophy (DMD). It is the first US Food and Drug Administration (FDA)-approved treatment for patients with DMD with a mutation amenable to skipping exon 45.

AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia

Under development by Amarin Corporation, AMR101 is a partially synthetic omega-3 fatty acid-based drug. It contains the

AMVUTTRA (vutrisiran) for the Treatment of Polyneuropathy of hATTR Amyloidosis, USA

AMVUTTRA™ (vutrisiran) is the first FDA-approved drug to reverse neuropathy impairment in hATTR amyloidosis patients.

AN2728 for the Treatment of Psoriasis

AN2728 is an anti-inflammatory drug being developed by Anacor Pharmaceuticals as a treatment for psoriasis.

Anacetrapib – Treatment for Atherosclerosis

Anacetrapib (MK-0859) is an orally active cholesteryl ester transfer protein (CETP) inhibitor indicated for the treatment of atherosclerosis.

Andexxa (coagulation factor Xa recombinant, inactivated-zhzo) for the Treatment of Factor Xa Inhibitor-Associated Acute Major Bleeding

Andexxa® (coagulation factor Xa recombinant, inactivated-zhzo) is an intravenous infusion indicated for the treatment of patients with factor Xa inhibitor-associated acute major bleeding.

Anoro Ellipta for Treatment of Chronic Obstructive Pulmonary Disease

Anoro ellipta (umeclidinium bromide / vilanterol) is a dry powder for inhalation, indicated for the treatment of airflow obstructions in patients suffering from chronic obstructive pulmonary disease (COPD) or emphysema.

Anthim (obiltoxaximab) Injection for the Treatment of Inhalational Anthrax

Anthim (obiltoxaximab) is an injectable drug developed by Elusys Therapeutics for the treatment of inhalational anthrax caused by bacillus anthracis.

APD125 – Therapy for Insomnia

Developed by Arena Pharmaceuticals, APD125 is an oral serotonin antagonist with potential for the treatment of insomnia.

Apretude (cabotegravir) for the Treatment of HIV-1 Pre-Exposure Prevention (PrEP)

Apretude (cabotegravir) is indicated for the treatment of HIV-1 PrEP to minimise the risk of HIV-1 infection.

Aptiom® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures

Aptiom (eslicarbazepine acetate) is a sodium channel inhibitor approved as an adjunctive treatment for partial-onset seizures in the US and Europe.

Arexvy (RSV vaccine) to Prevent Lower Respiratory Tract Disease (LRTD), USA

Arexvy is the world’s first respiratory syncytial virus vaccine to prevent lower respiratory tract disease in older adults.

Ariflo (Cilomilast) – Oral PDE-IV Inhibitor for

Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV inhibitor under development by GlaxoSmithKline Pharm

Aristada™ (aripiprazole lauroxil) for the Treatment of Schizophrenia

Aristada™ (aripiprazole lauroxil), discovered and developed by Alkermes, is an antipsychotic drug indicated for the treatment of schizophrenia in adults.

Artesunate for Injection for the Treatment of Severe Malaria

Artesunate for Injection is an antimalarial drug indicated for the initial treatment of severe malaria in adult and paediatric patients. It is the only drug in the US to treat the condition.

Arzerra (Ofatumumab) for the Treatment of Chronic Lymphocytic Leukaemia (CLL)

Arzerra (ofatumumab) is the first-line drug approved for the treatment of chronic lymphocytic leukaemia (CLL).

ASA404 Vascular Disrupting Agent for Solid Tumours

ASA404 is a vascular disrupting agent (VDA) that was being developed by Antisoma and Novartis as a treatment for a range

ASP-1929 for the Treatment of Head and Neck Squamous Cell Carcinomas

ASP-1929 is a first-in-class therapy indicated for the treatment of head and neck squamous cell carcinomas (HNSCC).

AstraZeneca’s Brilinta – Treatment for Acute Coronary Syndrome

Brilinta is an anti-platelet drug which decreases the platelet aggregation and prevents blood clots. It was developed by AstraZeneca for the treatment of acute coronary syndrome (ACS).

Atogepant for the Preventive Treatment of Migraine, US

Atogepant binds to the CGRP receptor on the brain’s trigeminal nerve and blocks the activation of the migraine.

Aubagio (Teriflunomide) for the Treatment of Multiple Sclerosis

Aubagio (teriflunomide) is an immunomodulatory agent indicated for the treatment of relapsing forms of multiple sclerosis (MS). It was developed by Genzyme.

Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease

Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

Auvelity (dextromethorphan and bupropion) for the Treatment of Major Depressive Disorder (MDD), USA

Auvelity™ (dextromethorphan and bupropion) is the first and only oral rapid-acting antidepressant for major depressive disorder.

Avastin (bevacizumab) – Angiogenesis Inhibitor and Cancer Therapy

The product of a joint development programme between Genentech and Roche, Avastin (bevacizumab) is a humanised monoclonal antibody (MAb) directed against vascular endothelial growth factor (VEGF), a pro-angiogenesis factor.

Aveed (testosterone undecanoate) for the Treatment of Men with Hypogonadism

Aveed (testosterone undecanoate) is a testosterone replacement therapy indicated for the treatment of hypogonadism in adult men who are associated with a deficiency or absence of the male hormone testosterone.

Axitinib – Treatment for Advanced Renal Cell Carcinoma

Inlyta (axitinib) was developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma.

AYVAKIT (avapritinib) for the Treatment of Gastrointestinal Stromal Tumours (GISTs)

AYVAKIT™ (avapritinib) is the first precision therapy approved for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumours (GISTs) and advanced systemic mastocytosis (ASM).

B

Balversa (erdafitinib) for the Treatment of Urothelial Carcinoma

Balversa™ (erdafitinib) is one of the first fibroblast growth factor receptor (FGFR) kinase inhibitors to be approved for the treatment of locally advanced or metastatic urothelial carcinoma.

Bamlanivimab (LY-Cov555) for the Treatment of Covid-19

Bamlanivimab (LY-CoV555) is a neutralising monoclonal antibody intended for the treatment of mild to moderate COVID-19.

Banzel – Treatment for Lennox-Gastaut syndrome

Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic seizures.

Bavencio (avelumab) for the Treatment of Metastatic Merkel Cell Carcinoma

Bavencio® (avelumab) is a human PD-L1 monoclonal antibody indicated for the treatment of metastatic Merkel-cell carcinoma (MCC).

Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Ligand Pharmaceuticals.

Belinostat (PXD 101) for the Treatment of Peripheral T-Cell Lymphoma (PTCL)

Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).

Belsomra (suvorexant) for the Treatment of Insomnia

Belsomra (suvorexant) is the only approved drug of its kind for treating adult patients suffering from insomnia characterised by difficulty with sleep onset or sleep maintenance. The drug was developed by Merck, Sharp & Dohme Corp.

Benlysta – Lupus Treatment

Benlysta is an investigational human monoclonal antibody drug indicated for treating autoantibody-positive systemic lupu

Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)

Beovu® (brolucizumab) is an anti-vascular endothelial growth factor (anti-VEGF) drug indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

BESPONSA (inotuzumab ozogamicin) for the Treatment of Acute Lymphoblastic Leukaemia

BESPONSA® is an intravenous infusion indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

BESREMi (ropeginterferon alfa-2B) for the Treatment of Polycythaemia Vera, US

BESREMi® (ropeginterferon alfa-2B) is a mono-pegylated proline interferon indicated for the treatment of polycythaemia vera.

Bevyxxa (betrixaban) for the Treatment of Venous Thromboembolism (VTE) in Adults

Bevyxxa (betrixaban) is a drug developed by Portola Pharmaceuticals that is indicated for the prevention and treatment of venous thromboembolism (VTE) in adults.

Bexsero – Treatment for Meningitis B (MenB) Disease

Discovered and developed by Novartis, Bexsero is a vaccine indicated for the treatment of meningococcal group B (MenB) disease. It is the first and the only Men B vaccine for the protection of all age groups against the disease.

Bifeprunox – Atypical Antipsychotic Drug

Bifeprunox mesilate was a novel atypical antipsychotic agent under development by Solvay Pharmaceuticals as a treatment

Biktarvy for the Treatment of HIV-I

Biktarvy® is a once-daily regimen indicated for the treatment of HIV-1 infection in adults that were previously not treated with anti-retroviral medicines.

Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia

Blincyto® (blinatumomab) is a monoclonal antibody indicated as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.

BNC105

BNC105, being developed by Adelaide-based Bionomics, is a new kind of drug known as a vascular targeting agent (VDA). As

Boceprevir, Experimental Drug for Chronic Hepatitis C Infection by Schering-Plough

Victrelis (boceprevir) is an oral HCV protease inhibitor indicated for the treatment of chronic infection with hepatitis

Boostrix – Vaccine for Whooping Cough, Tetanus and Diphtheria

Boostrix is a three-in-one vaccine administered to protect against whooping cough, tetanus and diphtheria. Vaccination is an effective way to protect against them.

Bosutinib – Chronic Myelogenous Leukaemia (CML) Treatment

Bosutinib is an investigational drug indicated for treating Philadelphia chromosome positive Chronic Myelogenous Leuka

Breo Ellipta for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) is a dry powder inhaler indicated for the long-term maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Brexafemme (ibrexafungerp) for the Treatment of Vaginal Yeast Infection

Brexafemme (ibrexafungerp) is the first FDA-approved oral non-azole treatment for vaginal yeast infections.

Breyanzi (lisocabtagene maraleucel) for the Treatment of Large B-cell Lymphoma (LBCL), USA

Breyanzi® is a CAR T cell therapy for second-line treatment of relapsed or refractory large B-cell lymphoma in adults.

Brintellix (Vortioxetine) for Treatment of Major Depressive Disorder (MDD)

Brintellix (vortioxetine) is a new multimodal antidepressant indicated for the treatment major depressive disorder (MDD) in adults.

Briumvi (ublituximab-xiiy) for the Treatment of Multiple Sclerosis, USA

Briumvi™ is the first and only approved anti-CD20 monoclonal antibody for treating relapsing forms of multiple sclerosis.

Briviact (brivaracetam) For the Treatment of Partial Onset Seizures

Briviact (brivaracetam) was developed by UCB for the treatment of partial onset of seizures in epilepsy patients over the age of 16.

Brukinsa (zanubrutinib) for the Treatment of Waldenstrom’s Macroglobulinaemia, USA

Brukinsa® (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor developed by BeiGene.

Bydureon® BCise™ for the Treatment of Type-2 Diabetes

Bydureon® BCise™ (exenatide extended-release) is an injectable suspension containing a glucagon-like peptide-1 (GLP-1) receptor agonist. 

Byetta (exenatide) – First-in-Class Incretin Mimetic for Type 2 Diabetes

Developed by Amylin Pharmaceuticals, Byetta (exenatide) is a synthetic exendin-4 agent indicated for the treatment of ty

Bylvay (odevixibat) for the Treatment of Pruritus, USA

Bylvay™ is indicated to treat skin itching caused by certain inherited liver conditions, PFIC and Alagille syndrome.

C

Cabenuva (cabotegravir and rilpivirine) for the Treatment of HIV-1 Infection, USA

Cabenuva is the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults.

Cablivi (caplacizumab) for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

Cablivi™ (caplacizumab) is a bivalent anti-Von Willebrand factor (vWF) nanobody indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP).

Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma

Cabometyx (cabozantinib) is used for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).

Calquence (acalabrutinib) for the Treatment of Mantle Cell Lymphoma

Calquence® (acalabrutinib) is a bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL).

Camzyos (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

Camzyos™ (mavacamten) is the only FDA-approved cardiac myosin inhibitor that targets the source of obstructive HCM.

Capravirine – Anti-Retroviral Drug

Developed by Pfizer Global Research and Development, capravirine is a Non-Nuclesoide Reverse Transcriptase Inhibitor (NN

Caprospinol, Therapy for Alzheimer’s Disease (AD)

Samaritan Pharmaceuticals' caprospinol (SP-233) is an investigational
agent under development for the treatment of Alzh

Carnexiv (carbamazepine) for the Treatment of Certain Seizure Types in Adults

Carnexiv (carbamazepine) is an injectable formulation developed by Lundbeck for partial, generalised tonic-clonic seizures in adult patients who are unable to temporarily take oral medication.

Carvykti (ciltacabtagene autoleucel) for the Treatment of Multiple Myeloma

Carvykti™ (ciltacabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory multiple myeloma (RRMM).

Ceftazidime-Avibactam for Treatment of Complicated Urinary Tract and Intra-Abdominal Infections

Ceftazidime-avibactam is an investigational antibiotic indicated for treatment of patients with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Actavis is jointly developing the drug in collaboration with AstraZeneca.

Ceftobiprole – Injectable Anti-MRSA Cephalosporin Antibiotic

The product of a joint development programme between the Swiss pharmaceutical company Basilea Pharmaceutica AG and Cilag AG International (a Johnson & Johnson company), ceftobiprole medocaril (BAL5788) is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.

Celvapan – H1N1 Pandemic Influenza Vaccine

The Celvapan pandemic vaccine is being developed by Baxter International. It was first developed as a mock-up vaccine co

Cepheid Xpert vanA Test Kit

Xpert vanA is a new diagnostic test kit developed by California-based Cepheid for the early and easy detection of vancom

Cerovive – Neuroprotectant for the

Cerovive, a nitrone-based free radical scavenger indicated for the treatment of acute ischaemic stroke has been disconti

Cervarix, Cervical Cancer Vaccine by GlaxoSmithKline

GlaxoSmithKline's (GSK) Cervarix is a prophylactic vaccine currently indicated for the prevention of precancerous cervic

Cetilistat – Investigational Drug for Obesity

Developed by Alizyme, a specialist biopharmaceutical company in collaboration with Takeda Pharmaceutical, cetilistat (AT

Chronic Plaque Psoriais Treatment with ILUMYA

ILUMYA™ (tildrakizumab-asmn) is a subcutaneous infusion indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

CIBINQO (abrocitinib) to Treat Moderate to Severe Atopic Dermatitis

CIBINQO (abrocitinib) is a once-daily, oral, prescription medicine to treat moderate to severe atopic dermatitis.

Cilansetron – New Treatment for IBS

Developed by Solvay Pharmaceuticals, cilansetron is a 5-HT3 antagonist indicated for the treatment of diarrhoea-predomin

CIMZIA (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis

CIMZIA® (certolizumab pegol) is a subcutaneous infusion indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype

Cinqair is an injectable formulation of reslizumab developed by Teva Pharmaceuticals for the treatment of severe asthma and eosinophilic phenotype in adults.

Columvi (Glofitamab-gxbm) for the Treatment of Diffuse Large B-Cell Lymphoma, USA

Columvi is a bispecific antibody, fixed-duration treatment for relapsed or refractory diffuse large B-cell lymphoma.

Contrave for the Treatment of Obesity

Contrave (Bupropion / naltrexone) is a drug indicated for treating obesity. The drug was developed by Orexigen Therapeutics.

COPIKTRA (duvelisib) Indicated for chronic lymphocytic leukaemia

COPIKTRA (duvelisib) is a dual phosphoinositide 3-kinase (PI3K) inhibitor indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) or follicular lymphoma (FL).

Corifact – Treatment for Rare Form of Haemophilia

Corifact is an intravenous drug indicated for the treatment of bleeding disorder in patients with factor XIII deficien

Corlanor (Ivabradine) for the Treatment of Heart Failure

Corlanor (ivabradine) is an oral medication approved to reduce the risk of hospitalisation for worsening heart failure in patients facing chronic heart failure risk due to the lower-left part of the heart not contracting well.

COSELA™ (trilaciclib) for the Treatment of Chemotherapy-Induced Myelosuppression, US

COSELA™ (trilaciclib) is the first approved myeloprotection therapy indicated to reduce the occurrence of chemotherapy-induced bone marrow suppression in adult patients.

Cosentyx (secukinumab) for Treatment of Plaque Psoriasis

Cosentyx (secukinumab), discovered and developed by Swiss pharmaceutical company Novartis International, is the first interleukin-17A (IL-17A) inhibitor drug approved for the treatment of moderate-to-severe psoriasis in adult patients.

COVAXIN™ (BBV152) for the Treatment of Covid-19, India

COVAXIN™ (BBV152) is the first Covid-19 vaccine developed completely in India.

Cresemba® (isavuconazonium sulphate) for the Treatment of Invasive Aspergillosis and Mucormycosis

Cresemba (isavuconazonium sulphate) is an antifungal drug indicated for the treatment of invasive aspergillosis and invasive mucormycosis, which is also known as zygomycosis.

Crysvita (burosumab-twza) for Treating X–Linked Hypophosphatemia

Crysvita® (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in adults and children.

Cuvposa – Treatment for Chronic Drooling

Cuvposa (Glycopyrrolate) is the first and only approved drug for controlling drooling in patients aged between three

CXL-1020 Treatment for Patients with Acute Decompensated Heart Failure (ADHF)

CXL-1020 is an investigational therapeutic agent being developed for treating patients with acute decompensated heart fa

Cymbalta (Duloxetine HCl) for Chronic Musculoskeletal Pain Management

Cymbalta (Duloxetine hydrochloride) is indicated for treating chronic musculoskeletal pain as a result of osteoarthritis

Cyramza (ramucirumab) for the Treatment of Gastric Cancer

Cyramza (ramucirumab) is a human monoclonal antibody for the treatment of Gastric cancer.

Cystaran (cysteamine hydrochloride) for Treatment of Cystinosis

Cystaran (cysteamine hydrochloride) is a cystine-depleting agent indicated for the treatment of cystinosis.

Cytalux (pafolacianine) for Identification of Ovarian Cancer

Cytalux is the first intraoperative fluorescent imaging drug that helps in identifying ovarian cancer lesions during surgery.

D

Daklinza (daclatasvir) for the Treatment of Chronic Hepatitis C Genotype 3 Infection

Daklinza (daclatasvir), an NS5A replication complex inhibitor, is the first 12-week, all-oral therapy indicated for use with sofosbuvir, for the treatment of hepatitis C (HCV) genotype 3 infections.

Daliresp (Roflumilast), Treatment to Reduce COPD

Daliresp (Roflumilast) is an oral tablet that is proved to reduce the risk of exacerbations in patients suffering from

Dalvabancin – Second-Generation Glycopeptide for Serious Gram-Positive Infections

Originally developed by Vicuron Pharmaceuticals (which was subsequently acquired by Pfizer and then Durata Therapeutics)

DANYELZA (naxitamab-gqgk) for the Treatment of Neuroblastoma

DANYELZA® (naxitamab-gqgk) is a humanised immunotherapy indicated in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of high-risk neuroblastoma (HR-NB).

Darapladib – Selective Lp-PLA2 Inhibitor for Prevention of Atherosclerosis

Darapladib is a selective LpPLA2 inhibitor under development by GlaxoSmithKline (GSK). The drug is targeted at coronary

Darzalex (daratumumab) for the Treatment of Multiple Myeloma

Darzalex (daratumumab) is the world's first human anti-CD38 monoclonal antibody (mAb) approved for the treatment of patients with multiple myeloma.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the Treatment of Light Chain (AL) Amyloidosis

DARZALEX FASPRO^® (daratumumab and hyaluronidase-fihj) is the first subcutaneous therapy approved for the treatment of newly diagnosed light chain (AL) amyloidosis in adult patients.

Dasatinib – Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML)

Dasatinib is a new, oral small-molecule tyrosine kinase inhibitor (TKI) developed by Bristol Myers Squibb for the trea

Defitelio (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease

Defitelio (defibrotide sodium) is an injectable drug developed by Jazz Pharmaceuticals, for the treatment of hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome, in adults and children with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

Delstrigo for the Treatment of HIV-1 Infection

Delstrigo™ is a fixed-dose combination tablet of antiretroviral drugs doravirine, lamivudine, and tenofovir disoproxil fumarate indicated for the treatment of human immunodeficiency virus (HIV) 1 infection.

Descovy (emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection

Descovy (emtricitabine200mg/tenofovir alafenamide25mg, F/TAF) is developed by Gilead sciences for the treatment of HIV-1 infection in adults and children above 12 years of age.

Dificid (fidaxomicin) – Narrow-Spectrum Antibiotic for Clostridium Difficile Infection

Dificid (fidaxomicin) is the first in a new class of antibiotics developed by Optimer Pharmaceuticals to treat Clostridi

Dimebon – Investigational Compound Indicated for the Treatment of Alzheimer’s and Huntington’s Disease

Dimebon (latrepirdine) is an investigational compound indicated for the treatment of Alzheimer's and Huntington's diseas

Dinutuximab beta for the Treatment of Neuroblastoma

Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above.

Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia

Doptelet® (avatrombopag) is one of the first thrombopoietin (TPO) receptor agonists to be approved in the US for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD).

Doripenem – A New Broad-Spectrum Carabapenem Antibiotic

Doripenem is part of Johnson &' Johnson's anti-infective R&D portfolio following the acquisition of Peninsula Ph

Dovato (dolutegravir/lamivudine) for the Treatment of HIV Infection

Dovato® (dolutegravir/lamivudine) is a two-drug regimen indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) in adults.

Duaklir Genuair for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Duaklir Genuair (aclidinium bromide / formoterol fumarate) is an inhalation powder indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD).

Dulera (Mometasone Furoate and Formoterol Fumarate Dihydrate) – Treatment for Asthma

Dulera (mometasone furoate and formoterol fumarate dihydrate) is a new fixed-dose combination inhaler for the treatment of asthma.

Dupixent (dupilumab) for the Treatment of Atopic Dermatitis

Dupixent (dupilumab) is indicated for the treatment of moderate to severe atopic dermatitis and asthma in adults and children.

Durlaza (aspirin) for Reducing Risk of Cardiovascular Events

Durlaza (aspirin) is a non steroidal anti-inflammatory drug indicated for the prevention of thrombotic events in patients with cardiovascular disease (CVD).

Duzallo (allopurinol and lesinurad) for the Treatment of Hyperuricemia Associated with Gout

Duzallo (allopurinol and lesinurad) is indicated for the treatment of hyperuricemia associated with uncontrolled gout. It contains urate transporter-1 (URAT-1) inhibitor blended with xanthine oxidase inhibitor (XOI).

Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Paediatric Patients

Dysport (abobotulinumtoxinA) is an injectable formulation developed by Ipsen Biopharmaceuticals for the treatment of lower limb spasticity in paediatric patients aged two years or older.

E

Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection

Ebanga (ansuvimab-zykl) is a Zaire ebolavirus glycoprotein (EBOV GP)-directed human monoclonal antibody for the treatment of Zaire ebolavirus infection in adult and paediatric patients.

Edarbi for the Treatment of Hypertension

Edarbi (Azilsartan medoxomil) was developed by Takeda Pharmaceuticals for the treatment of hypertension in adults.

Edoxaban, Oral Anticoagulant

Lixiana (edoxaban) is an oral anticoagulant developed by Daiichi Sankyo, a pharmaceutical company based in Japan. It is

Edurant (rilpivirine) for the Treatment of HIV-1 Infection

Edurant (rilpivirine) is an antiviral drug indicated for treatment-naive adults with HIV-1 infection.

Elacytarabine (CP-4055) for Treatment of Acute Myeloid Leukaemia

Elacytarabine (CP-4055) is a lipid-conjugated version of cytarabine, an anti-cancer agent drug approved for the treatmen

Elelyso (Taliglucerase Alfa) for Treating Gaucher Disease

Elelyso (taliglucerase alfa) is an intravenous drug indicated for the treatment of type one Gaucher disease. The drug was jointly developed by Protalix BioTherapeutics and Pfizer.

Eliquis (apixaban) for Prevention of Stroke in Nonvalvular Atrial Fibrillation (NVAF) Patients

Eliquis (apixaban) is an anticoagulant drug that was jointly developed by Bristol-Myers Squibb and Pfizer.

Eloctate™ for the Treatment of Haemophilia A

Eloctate is a drug approved for the control and prevention of bleeding episodes in children and adult haemophilia A patients.

Elotuzumab – Anti-CS1 Antibody for Multiple Myeloma

Elotuzumab (HuLuc63) is an anti-CS1 humanised monoclonal antibody (MAb) developed by PDL Biopharma. In December 2008 PDL

Elzonris (tagraxofusp-erzs) for the Treatment of BPDCN

Elzonris™ (tagraxofusp-erzs) is an interleukin-3 receptor alpha chain (CD123) directed cytotoxin that is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and paediatric patients.

Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy

Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for treatment of patients aged two years and older suffering from duchenne muscular dystrophy (DMD).

EMPAVELI (pegcetacoplan) for the Treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)

EMPAVELI™ (pegcetacoplan) is the first and only targeted complement component 3 (C3) therapy indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults.

Empliciti (elotuzumab) for the Treatment of Multiple Myeloma

Empliciti (elotuzumab) is an immunostimulatory antibody indicated for the treatment of multiple myeloma.

Enbrel – Immunosuppressant for Treatment of Rheumatoid Arthritis

Enbrel is an immunosuppressant that inhibits the production of tumour necrosis factor (TNF) in patients suffering from r

Endari for the Treatment of Sickle Cell Disease

Endari™ is an orally administered powdered form of amino acid L-glutamine indicated for the treatment of sickle-cell disease.

ENHERTU (fam-trastuzumab deruxtecan-nxki) for the Treatment of HER2 Positive Advanced Gastric Cancer

Enhertu is a HER2-directed antibody-drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo.

Enjaymo™ (sutimlimab-jome) for the Treatment of Cold Agglutinin Disease (CAD)

Enjaymo™ (sutimlimab-jome) is a classical complement inhibitor that works by inhibiting the haemolysis of red blood cells.

Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Enspryng™ (satralizumab-mwge) is the first and only US Food and Drug Administration (FDA)-approved subcutaneous therapy indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody-positive adult patients.

Entecavir (Baraclude) – Oral Antiviral Drug for Hepatitis-B Infection

Discovered by Bristol-Myers Squibb (BMS), Entecavir / Baraclude is an antiviral drug for treating chronic Hepatitis B.

Entresto (Sacubitril / Valsartan) for the Treatment of Heart Failure

Entresto (sacubitril/valsartan) is an angiotensin II receptor blocker indicated for the treatment of chronic heart failure.

Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease

Entyvio (vedolizumab) is a human monoclonal antibody indicated for treating adult patients with moderate to severe ulcerative colitis (UC) and those with moderate to severe Crohn's disease (CD).

Epanova for the Treatment of Hypertriglyceridemia

Epanova (omega-3-carboxylic acids) is indicated for the treatment of adult patients with severe hypertriglyceridaemia.

Epclusa (Sofosbuvir/ Velpatasvir) for the Treatment of Hepatitis C

Epclusa (Sofosbuvir/ Velpatasvir) is an oral formulation developed by Gilead Sciences for the treatment of 1-6 chronic hepatitis C virus (HCV) infection.

EPIDIOLEX (cannabidiol) for Seizures Associated with Lennox-Gastaut and Dravet Syndromes

EPIDIOLEX® is a cannabidiol (CBD) based drug indicated for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).

Epkinly (epcoritamab-bysp) for the Treatment of Diffuse Large B-Cell Lymphoma, USA

Epkinly™ (epcoritamab-bysp) is the first bispecific antibody to treat adults with diffuse large B-cell lymphoma.

Erbitux (Cetuximab)

Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for the epidermal growth factor receptor (EGFR). A new

Erivedge (vismodegib) – Treatment for Advanced Basal Cell Carcinoma

Erivedge (vismodegib) is a Hedgehog pathway inhibitor indicated for the treatment of advanced basal cell carcinoma (BCC) in adults.

Erleada (apalutamide) for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

Erleada™ (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).

Erwinaze (Asparaginase Erwinia Chrysanthemi) – Treatment for ALL

Erwinaze (asparaginase Erwinia chrysanthemi) is indicated for the treatment of acute lymphoblastic leukaemia (ALL). It is manufactured by EUSA Pharma.

Eskata (hydrogen peroxide) for the Treatment of Raised Seborrheic Keratoses (SK), USA

Eskata® (hydrogen peroxide) is a topical, non-invasive treatment for raised seborrheic keratoses (SK) in adults.

Esperoct (turoctocog alfa pegol) for the Treatment of Haemophilia A

Esperoct® (turoctocog alfa pegol) is a recombinant factor indicated for the treatment of haemophilia A in adults and children.

ETC-216 – Phospholipid

Developed by US biopharmaceutical company Esperion Therapeutics, ETC-216 is a synthetic variant of high-density lipoprot

Eviplera – Treatment for HIV

Eviplera is a single-pill regimen targeted at human immunodeficiency virus-1 (HIV-1). It combines the active substances emtricitabine, rilpivirine and tenofovir disoproxil.

Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection

Evotaz (atazanavir and cobicistat) is a protease inhibitor indicated for the treatment of HIV-1 infection in adults.

Evrysdi (risdiplam) for the Treatment of Spinal Muscular Atrophy (SMA)

Evrysdi™ (risdiplam) is the first and only oral medication indicated for the treatment of spinal muscular atrophy (SMA) in patients of two months of age and older.

Evusheld (tixagevimab and cilgavimab) for the Prevention of Covid-19

Evusheld is a long-acting antibody combination therapy for the pre-exposure prevention of Covid-19 in high-risk patients.

Exanta – Oral Direct Thrombin Inhibitor for the

Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI) under development by AstraZeneca. As the first fixed-do

Exjade (Deferasirox) for Treating Chronic Iron Overload, US

Exjade (deferasirox) is an oral iron chelator developed and manufactured by Novartis. It is indicated for the treatment of iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes.

Exkivity (mobocertinib) for the Treatment of Non-Small Cell Lung Cancer

Exkivity is the first and only oral therapy indicated for non-small cell lung cancer with EGFR exon 20 insertion mutations.

Exondys 51 (eteplirsen) for the Treatment of Duchenne Muscular Dystrophy (DMD)

Exondys 51 (eteplirsen) is an injectable solution developed by Sarepta Therapeutics.

Exparel for Postsurgical Pain Relief

Exparel is a non-opioid analgesic, developed to provide postsurgical pain relief. It is a long acting liposome injection of bupivacaine, a drug widely used to treat postsurgical pain.

Exubera – Inhaled Insulin

The product of a joint development programme between Aventis and Pfizer, Exubera is an inhaled short-acting insulin prep

Eylea (Aflibercept) for Treatment for Wet AMD

Eylea (aflibercept), a recombinant fusion protein, was developed for the treatment of patients with wet age-related macular degeneration (AMD).

F

Fablyn (Lasofoxifene) – Investigational SERM

The product of a joint development programme between Pfizer and Ligand Pharmaceuticals, Fablyn, formerly Oporia (lasofoxifene) is a selective oestrogen receptor modulator (SERM).

Fampridine-SR – Treatment for Multiple Sclerosis

Developed by Acorda Therapeutics and manufactured by Elan Corporation, fampridine-SR (now referred to as AMPYRA) is a se

Farydak® (panobinostat) for the Treatment of Multiple Myeloma

Farydak (panobinostat, previously known as LBH589) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients with multiple myeloma.

Fasenra (benralizumab) for the Treatment of Asthma

Fasenra (benralizumab) is a monoclonal antibody (mAb) indicated for the treatment of severe eosinophilic asthma in patients aged 12 years and older.

Faslodex (fulvestrant) for the Treatment of Advanced Breast Cancer

Faslodex (fulvestrant) is an oestrogen receptor antagonist indicated for the treatment of locally advanced or metastatic breast cancer.

FETROJA (cefiderocol) for the Treatment of Bacterial Pneumonia

FETROJA® (cefiderocol) is the first approved siderophore cephalosporin antibacterial drug.

Fetzima (Levomilnacipran) – Treatment for Major Depressive Disorder (MDD)

Fetzima (levomilnacipran) is an antidepressant indicated for treatment of adult patients suffering from major depressive disorder (MDD).

Fiasp (insulin aspart) for the Treatment of Type 1 and Type 2 Diabetes

Discovered and developed by Novo Nordisk, Fiasp® (insulin aspart) is a fast-acting insulin analogue indicated for the treatment of adults with Type 1 and Type 2 diabetes.

Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy, USA

Filspari (sparsentan) is the first approved non-immunosuppressive therapy for reducing proteinuria in IgA nephropathy.

Fingolimod – Novel Therapy for Multiple Sclerosis

Fingolimod (branded Gilenya) is an innovative treatment for multiple sclerosis (MS) under development by Novartis. The d

FINTEPLA (Fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome, USA

FINTEPLA® (fenfluramine) is indicated to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.

FIRAZYR – Treatment for Hereditary Angioedema

FIRAZYR (Icatibant) is a drug developed and manufactured by Jerini, which was taken over by Shire Pharmaceuticals in 2008. The drug is indicated for the treatment of Hereditary Angioedema (HAE).

Firdapse (amifampridine) for Lambert-Eaton Myasthaenic Syndrome

Firdapse® (amifampridine) is one of the first drugs to be approved for the treatment of Lambert-Eaton myasthaenic syndrome (LEMS) in adults.

Florbetaben

Alzheimer's disease (AD) is the most common type of dementia, which severely impacts the intellectual abilities of a

Flucelvax Vaccine for Protection Against Seasonal Influenza

Flucelvax, developed by Novartis in association with the US Department of Health and Human Services, is a vaccine that provides protection against seasonal influenza for adult patients aged 18 years and above.

Fludase – Experimental Antiviral Drug for Influenza

NexBio, a US start-up biopharmaceutical company that specialises in developing antiviral agents, has pioneered the development of Fludase (DAS181).

FluLaval Influenza Virus Vaccine

FluLaval is an influenza vaccine that was approved by the US FDA on 23 July 2010, for use on people who are 18 years and

Flurizan – Anti-Amyloid Drug for Treatment of Alzheimer’s Disease

Myriad Pharmaceuticals' Flurizan (tarenflurbil) is a selective amyloid lowering agent under development for the treatmen

Flutiform (fluticasone proprionate and formoterol fumarate) for Treatment of Asthma

Flutiform (fluticasone proprionate and formoterol fumarate) is a combination therapy used for the treatment of asthma.

Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes

Forxiga (dapagliflozin) is a type 2 diabetes drug jointly developed by AstraZeneca and Bristol-Myers Squibb (BMS). It is the first SGLT2 (sodium / glucose cotransporter 2) class drug developed by BMS and AstraZeneca.

FOTIVDA (tivozanib) for the Treatment of Renal Cell Carcinoma

FOTIVDA® (tivozanib) is an oral tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC) in adult patients.

Fulyzaq (Crofelemer) for the Treatment of HIV / AIDS-Associated Diarrhoea

Fulyzaq (crofelemer) is an anti-infective drug which is derived from a botanical source. It is indicated for the treatment of non-infectious diarrhoea in HIV / AIDS patients who are on anti-retroviral therapy (ART).

Fycompa (perampanel) – Treatment for Epilepsy

Fycompa (perampanel / E2007) is an AMPA-type glutamate receptor antagonist indicated for the treatment of epilepsy. It was developed by Japan-based healthcare company Eisai.

G

Gaboxadol – Investigational Agent

Gaboxadol is a direct-acting gamma-amino butyric acid (GABA)A agonist under development by Danish pharmaceutical company

Galafold (migalastat) Indicated for the Treatment of Fabry Disease

Galafold™ (migalastat) is indicated for the treatment of adult patients aged 16 years and older with Fabry disease.

Galida – Dual PPAR

AstraZeneca's, Galida (tesaglitazar) is a dual-acting oral Peroxisome Proliferator-Activated Receptor (PPAR) agonist tha

Gamifant (emapalumab-lzsg) for Primary Haemophagocytic Lymphohistiocytosis

Gamifant® (emapalumab-lzsg) is an interferon-gamma (IFNγ) blocking antibody indicated for the treatment of primary haemophagocytic lymphohistiocytosis (HLH) in paediatric and adult patients.

Gardasil 9 Vaccine for Prevention of Cancers Caused by Human Papillomavirus (HPV)

Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) is indicated for the prevention of cancers caused by some types of human papillomavirus (HPV).

Gattex (Teduglutide) for Treatment of Short Bowel Syndrome (SBS)

Gattex (teduglutide) is a subcutaneous injection indicated for the treatment of adult patients with short bowel syndrome (SBS). The drug was developed and manufactured by NPS Pharmaceuticals in association with Takeda Pharmaceuticals.

Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Gavreto™ (pralsetinib) is a targeted therapy indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), diagnosed by a US Food and Drug Administration (FDA)-approved test, in adult patients.

Gazyva (obinutuzumab) for the Treatment of Chronic Lymphocytic Leukaemia (CLL)

Gazyva (obinutuzumab / GA101) is a monoclonal antibody indicated for the treatment of chronic lymphocytic leukaemia (CLL).

GEMTESA for the Treatment of Overactive Bladder, US

GEMTESA’s long-term safety, tolerability, and efficacy in adults with OAB was evaluated in a 40-week Phase III EMPOWUR extension study.

Gilotrif (afatinib) for the Treatment of Metastatic Non-Small cell Lung Cancer

Gilotrif (afatinib) is an orally administered drug that is indicated as the first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.

Givlaari™ (givosiran) for the Treatment of Acute Hepatic Porphyria

Givlaari™ (givosiran) is the first aminolevulinic acid synthase 1 (ALAS1)-targeting RNAi drug indicated for the treatment of acute hepatic porphyria (AHP) in adults.

Glatopa (glatiramer acetate injection) for the Treatment of Multiple Sclerosis

Glatopa (glatiramer acetate injection, formerly M356) is the first substitutable generic drug approved for the treatment of relapsing-remitting multiple sclerosis (RRMS).

GLS-5700 DNA Vaccine for Prevention of Infection from Zika Virus

GLS-5700 is a synthetic vaccine being developed by Inovio Pharmaceuticals and GeneOne Life Sciences to prevent and treat infections caused by the Zika virus.

Glybera (alipogene tiparvovec) for Treatment of Lipoprotein Lipase Deficiency (LPLD)

Glybera (alipogene tiparvovec) is a gene therapy indicated for the treatment Lipoprotein Lipase Deficiency (LPLD). It was developed by Amsterdam Molecular Therapeutics (AMT), which was acquired by uniQure in April 2012.

GRNOPC1 for spinal-cord injury

GRNOPC1 is an indicative stem cell therapy developed by Geron for the treatment of spinal cord injuries (SCI).

H

Haegarda for the Preventive Treatment of Hereditary Angioedema

Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.

Halaven – Treatment of Metastatic Breast Cancer

Halaven is a non-taxane drug developed by Eisai Co. for the treatment of metastatic breast cancer.

Halaven (eribulin mesylate) for the Treatment of Advanced Liposarcoma

Halaven (eribulin mesylate) is an injectable chemotherapy drug developed by Eisai for the treatment of unresectable or metastatic liposarcoma patients that previously received anthracycline-based chemotherapy.

Harvoni (ledipasvir/sofosbuvir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection

Developed by Gilead Sciences, Harvoni (ledipasvir/sofosbuvir) is the first combination pill approved for the treatment of adult patients with chronic hepatitis C genotype 1 infection.

Hemlibra® (emicizumab-kxwh) for the Treatment of Haemophilia A with Inhibitors

Hemlibra® (emicizumab-kxwh) is an antibody indicated to reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

Herzuma (trastuzumab biosimilar) for the Treatment of Breast and Gastric Cancers

Herzuma® (trastuzumab biosimilar / CT-P6) is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.

Hetlioz (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder

Hetlioz (tasimelteon) is the first and only drug approved in the European Union (EU) for non-24-hour sleep-wake disorder (Non-24).

Hizentra for the Treatment of Patients with CIDP

Hizentra® (immune globulin subcutaneous 20% liquid) is a subcutaneous infusion indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Horizant – Treatment for Restless Legs Syndrome

Horizant is a non-dopaminergic therapy indicated for the treatment of restless legs syndrome (RLS). It was developed by XenoPort and is marketed by GSK in the US.

HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis

HUMIRA is the only subcutaneous therapy approved by the US Food and Drug Administration (FDA) for the treatment of ulcerative colitis in paediatric patients aged five years and above.

Humira for the Treatment of Hidradenitis Suppurativa

Humira (adalimumab) is a monoclonal antibody indicated for the treatment of more than ten indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa (HS), and uveitis.

Hycamtin – Anti-Tumour Drug for Treatment of Relapsed Small Cell Lung Cancer

Hycamtin is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for relapsed small cell lung cancer (S

Hydroxychloroquine for Potential Covid-19 Treatment

Hydroxychloroquine, marketed by Sanofi under the trade name Plaquenil, is primarily indicated for the treatment of malaria, discoid and systemic lupus erythematosus, and rheumatoid arthritis.

I

Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer

Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy.

Iclusig (ponatinib) for the Treatment of Chronic Myeloid Leukaemia

Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ALL). The drug is discovered, developed and marketed by Ariad Pharmaceuticals.

Idelvion for the Treatment of Haemophilia B

Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) is an injectable formulation developed by CSL Behring, for the treatment of haemophilia B in children and adults.

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML).

Idraparinux – Investigational Agent for Treatment and Prevention of Thromboembolic Events

The product of a joint development programme between Sanofi-Aventis (formerly Sanofi-Synthelabo) and Organon, Idraparinux is a new addition to the family of anticoagulant drugs.

Ilaris (canakinumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis

Ilaris (canakinumab) is a subcutaneous injection indicated for the treatment of systemic juvenile idiopathic arthritis (SJIA).

Iloperidone – Atypical Antipsychotic for Schizophrenia

Iloperidone is a dual-acting dopamine and serotonin receptor antagonist, developed originally by Titan Pharmaceuticals a

Iluvien for the Treatment of Diabetic Macular Oedema

Iluvien is indicated for the treatment of diabetic macular oedema, an eye disease that affects the retina.

Imbruvica (Ibrutinib) for the Treatment of Mantle Cell Lymphoma (MCL)

Imbruvica (ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of mantle cell lymphoma (MCL) patients that previously received at least one therapy.

IMCIVREE (setmelanotide) for Chronic Weight Management in Bardet-Biedl Syndrome Patients, USA

IMCIVREE® (setmelanotide) is the first approved treatment for managing weight in Bardet-Biedl syndrome patients.

Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Imfinzi™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC).

Imlygic (talimogene laherparepvec) for the Treatment of Cutaneous, Subcutaneous and Nodal Lesions

Developed by Amgen, Imlygic (talimogene laherparepvec) is the first injectable formulation of altered herpes simplex virus type 1 for the treatment of cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrence after initial surgery.

Inbrija for the Treatment of OFF Episodes in Parkinson’s Disease, USA

Inbrija is indicated for OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa medicine.

INCB9471 – CCR5 Antagonist for Treatment of HIV Infection

Under development by Incyte Corporation, INCB9471 is an experimental small molecule drug indicated for the treatment of

Incivek / Telaprevir – Treatment for Chronic Hepatitis C

Incivek (telaprevir) is a protease inhibitor used for treating hepatitis C infections in liver patients.

Incruse Ellipta for the Treatment Chronic Obstructive Pulmonary Disease (COPD)

IncruseTM (unmeclidinium) Ellipta is the first approved anticholinergic indicated as a maintenance treatment to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adult patients.

Indinavir – First-Generation HIV Protease Inhibitor

Merck's Crixivan (indinavir sulphate) is a first-generation HIV-protease inhibitor. Drugs such as indinavir have demonst

Influenza A (H1N1) Monovalent Vaccine by Sanofi Pasteur

Sanofi Pasteur's Influenza A (H1N1) 2009 Monovalent Vaccine for 2009 Influenza A (H1N1) or swine flu is one of the f

Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia

Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD).

INMAZEB for the Treatment of Zaire Ebolavirus Infection

INMAZEB™ (atoltivimab, maftivimab, and odesivimab) is the first antiviral antibody therapeutics approved for the treatment of Zaire ebolavirus infection in adults and children, including newborns whose mothers tested positive for the infection.

Inspra (Eplerenone)

Inspra (eplerenone) is indicated for the treatment of chronic heart failure. It was developed by Pharmacia Corporation,

Intermezzo – Treatment for Insomnia

Intermezzo is a formulation of zolpidem that is indicated for the treatment of insomnia or sleeping disorders. The drug

Invega Hafyera (paliperidone palmitate) for the Treatment of Schizophrenia

Invega Hafyera™ (paliperidone palmitate) is a long-acting atypical antipsychotic drug indicated for the treatment of schizophrenia.

Invega Trinza (paliperidone palmitate) for the Treatment for Schizophrenia

Invega Trinza (paliperidone palmitate), an atypical antipsychotic, is a three-month injection that is the first, and only, four-times-a-year drug indicated to treat schizophrenia .

Invokamet XR for the Treatment of Type 2 Diabetes in Adults

Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults.

Invokana (canagliflozin) for the Treatment of Type 2 Diabetes

Invokana (canagliflozin) is indicated to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. It was first developed by Mitsubishi Tanabe Pharma Corporation in Japan and later licensed to Janssen Pharmaceuticals.

Iomab-B for the treatment of Refractory and Relapsed Acute Myeloid Leukaemia

Iomab-B is a radio-immunotherapeutic drug developed by Actinium Pharmaceuticals for treatment of refractory and relapsed acute myeloid leukaemia in elderly patients.

Istaroxime

Istaroxime is an investigational drug for acute decompensated heart failure under development by Debiopharm of Switzerla

Isturisa (osilodrostat) for the Treatment of Cushing’s Disease

Isturisa® (osilodrostat) is the first cortisol synthesis inhibitor indicated for the treatment of Cushing's disease in adult patients, who are ineligible or failed pituitary surgery.

Ixempra (Ixapebilone) chemotherapeutic agent – New Cancer Therapy

Bristol-Myers Squibb's (BMS) ixabepilone (epothilone B) is a new chemotherapeutic agent that is currently in development

Ixinity for Treatment for Haemophilia B

Ixinity (coagulation factor IX (recombinant)) is an intravenous injection containing recombinant human coagulation factor IX that is indicated for the control and prevention of bleeding episodes in patients suffering from haemophilia B.

Izervay for the Treatment of GA, US

Izervay is available as a clear to slightly opalescent, colourless to slightly yellow solution.

J

Jakafi (ruxolitinib) – Treatment of Myelofibrosis

Jakafi (ruxolitinib) is an oral janus kinase (JAK) inhibitor indicated for the treatment of myelofibrosis. It was developed by Incyte Corp in collaboration with Novartis.

Januvia – Treatment of Diabetes Type 2

Januvia (sitagliptin phosphate) is an antihyperglycaemic drug containing an orally active inhibitor of the dipeptidyl pe

Jardiance (empagliflozin) for the treatment of heart failure with reduced ejection fraction (HFrEF)

Jardiance® (empagliflozin) is an SGLT2 inhibitor indicated to treat heart failure in adults with reduced ejection fraction.

Jardiance (empagliflozin) for the Treatment of Type 2 Diabetes

Jardiance (empagliflozin) is a once-daily tablet indicated for the treatment of adult patients with type 2 diabetes. The drug is developed and marketed by Boehringer Ingelheim Pharmaceuticals in collaboration with Eli Lilly and Company.

Jaypirca (pirtobrutinib) for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, USA

Jaypirca™ is a first-of-a kind BTK inhibitor for the treatment of mantle cell lymphoma in previously treated patients.

Jemperli (dostarlimab-gxly) for the Treatment of Advanced Solid Tumours, US

Jemperli is the first anti-PD-1 therapy for the treatment of certain types of endometrial cancer in Europe.

Jesduvroq (daprodustat) for the Treatment of Anaemia of Chronic Kidney Disease on Dialysis, USA

Jesduvroq (daprodustat) is the first oral treatment for anaemia caused by chronic kidney disease in adults undergoing dialysis.

Jetrea (ocriplasmin) for Treatment of Symptomatic Vitreomacular Adhesion

Jetrea (ocriplasmin) is a pharmacological agent developed by ThromboGenics, for the treatment of Symptomatic Vitreomacular Adhesion (VMA).

Juluca (Dolutegravir and Rilpivirine) for the Treatment of HIV-1 Infection

Juluca® (Dolutegravir and Rilpivirine) is a two-drug regimen indicated for the maintenance treatment of HIV-1 infection in adults.

Juxtapid (lomitapide) for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Juxtapid (lomitapide) is developed and manufactured by Aegerion Pharmaceuticals for the treatment of patients affected with homozygous familial hypercholesterolemia (HoFH).

JYNARQUE™ (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

JYNARQUE™ (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

JYNNEOS Vaccine for the Prevention of Smallpox and Monkeypox

JYNNEOS™ is a non-replicating vaccine indicated for smallpox and monkeypox disease prevention in adults aged 18 years and older.

K

Kadcyla (Trastuzumab Emtansine) for Treatment of Breast Cancer

Kadcyla (trastuzumab emtansine) is an antibody drug conjugate indicated for the treatment of HER2-positive metastatic breast cancer (mBC). The drug has been developed by Genentech (a member of the Roche Group).

Kalbitor – Treatment for Hereditary Angioedema

Kalbitor (ecallantide) is a drug developed by US-based Dyax Corp for the treatment of hereditary angioedema (HAE).

Kalydeco (Ivacaftor) – Treatment for Cystic Fibrosis

Kalydeco (Ivacaftor / VX-770) is a cystic fibrosis transmembrane conductor regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF).

KamRAB/KedRAB (rabies immunoglobulin human) for the Treatment of Rabies

KamRAB/KedRAB™ is a human rabies immunoglobulin (HRIG) indicated for the treatment of passive, transient post-exposure prophylaxis (PEP) of rabies infection. The drug was jointly developed by Kamada and Kedrion Biopharma.

Kanuma (sebelipase alfa) for the Treatment of Lysosomal Acid Lipase Deficiency (LAL-D)

Kanuma™ (sebelipase alfa) is an enzyme replacement therapy (ERT) for the treatment of patients of all ages with lysosomal acid lipase deficiency (LAL-D).

Kengreal (cangrelor) for Reducing Thrombotic Events During Percutaneous Coronary Intervention (PCI)

Kengreal (cangrelor) is the first and only intravenous anti-platelet agent indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing thrombotic events.

KERENDIA (finerenone) for the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes, USA

KERENDIA® is the first, nonsteroidal mineralocorticoid receptor antagonist for diabetes-related chronic kidney disease.

Kesimpta (ofatumumab) for the Treatment of Relapsing Multiple Sclerosis (RMS)

Kesimpta® (ofatumumab) is the first and only self-administered, targeted B-cell therapy indicated for the treatment of patients with relapsing multiple sclerosis (RMS) including clinically isolated syndrome (CIS), relapsing-remitting (RRMS), and active secondary progressive multiple sclerosis (SPMS).

Keveyis for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis

Keveyis (dichlorphenamide) is the first medicine indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, which are a group of rare hereditary disorders that cause occasional episodes of muscle weakness or paralysis.

Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis

Kevzara® (sarilumab) is a human monoclonal antibody indicated for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).

Keytruda (pembrolizumab) for the treatment of metastatic melanoma

Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) immunotherapy developed by Merck to treat melanoma.

Kineret (anakinra) for the Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

Kineret (anakinra) is a recombinant protein drug which was originally discovered and developed by Amgen. The drug was later licensed to Swedish Orphan Biovitrum (Sobi) in December 2008.

Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer

Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer in post-menopausal women.

Korlym (Mifepristone) for Treatment of Endogenous Cushing’s Syndrome

Korlym (mifepristone) is a glucocorticoid receptor blocker indicated for the control of high blood sugar levels in adult patients suffering from endogenous Cushing's syndrome.

Korsuva (difelikefalin) for the Treatment of Pruritus Associated with Chronic Kidney Disease

Korsuva (difelikefalin) is the first US FDA-approved treatment for moderate-to-severe pruritus in adult patients on haemodialysis.

Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1 (NF1)

Koselugo® (selumetinib) is the first FDA-approved drug indicated for the treatment of neurofibromatosis type 1 (NFI), a rare and incurable genetic condition, developed and commercialised globally by AstraZeneca and Merck (MSD) under a licensing agreement.

Kovaltry (Anti-haemophilic Factor VII (Recombinant)) for the Treatment of Haemophilia A

Kovaltry (Anti haemophilic Factor VII (Recombinant)) is developed by Bayer as the treatment for children and adult patients with haemophilia A.

Krazati (adagrasib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC), USA

Krazati™ (adagrasib) is a targeted treatment for advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation.

KRX-0401 Perifosine

KRX-0401 (perifosine) is a potential oral anti-cancer agent that suppresses the pathways associated with the programmed

Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia, USA

Kymriah (tisagenlecleucel) is the first FDA-approved CAR-T therapy indicated for treating ALL.

KYNMOBI for the Treatment of OFF episodes in Parkinson’s Disease, USA

KYNMOBI is the first and only sublingual therapy indicated for the on-demand treatment of OFF episodes in Parkinson's disease.

Kyprolis (carfilzomib) for Treatment of Multiple Myeloma

Kyprolis (carfilzomib), developed and manufactured by Onyx Pharmaceuticals, is a proteasome inhibitor indicated for the treatment of the patients with multiple myeloma.

L

Lamictal – Approved Treatment for Epilepsy and Bipolar

Lamictal XR (lamotrigine), developed by GlaxoSmithKline, is an approved treatment for epilepsy and bipolar I disease. Th

Lampit (nifurtimox) for the Treatment of Chagas Disease

Lampit® (nifurtimox) is an antiprotozoal medication indicated for the treatment of Chagas disease (American Trypanosomiasis) in paediatric patients from birth to less than 18 years of age and weighing at least 2.5kg.

Lamzede (velmanase alfa) to Treat Alpha-Mannosidosis

Lamzede® (velmanase alfa) is one of the first enzyme replacement therapies indicated for the treatment of non-neurological symptoms of patients with mild-to-moderate alpha‑mannosidosis.

Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma

Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection.

Latuda (lurasidone HCl) for the Treatment of Schizophrenia

Latuda (lurasidone HCl) is indicated for the treatment of schizophrenia. The drug was developed by Sunovion Pharmaceut

Lenvima™ (Lenvatinib Mesylate) for the Treatment of Thyroid Cancer

Lenvima™ (lenvatinib mesylate) is a multiple receptor tyrosine kinase (RTK) inhibitor indicated for the treatment of thyroid cancer.

Leqembi (lecanemab-irmb) for the Treatment of Alzheimer’s Disease, USA

Leqembi™ is the second FDA-approved anti-amyloid antibody for Alzheimer disease, after Biogen’s aducanumab.

Leqvio for the Treatment of Hypercholesterolaemia, US

Patients need to be administered two maintenance doses of the drug a year via syringe, following an initial dose and another at three months.

Lexapro – Treatment of Major Depressive Disorder in Adolescents

In March 2009, the US Food and Drug Administration (FDA) approved the supplemental new drug application (sNDA) of Forest

Libtayo (cemiplimab-rwlc) for the Treatment of Advanced Non-Small Cell Lung Cancer

Libtayo (cemiplimab-rwlc) is an advanced fully human monoclonal antibody indicated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients ineligible to undergo curative surgery or radiation therapy.

Licofelone – Novel Analgesic and Anti-Inflammatory Agent for Osteoarthritis

Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and La

Linzess (linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation, USA

Linzess (linaclotide) is a guanylate cyclase-C (GC-C) receptor agonist co-developed by AbbVie and Ironwood Pharmaceuticals.

Lipaglyn (Saroglitazar) for Treating Hypertriglycerdaemia in Type 2 Diabetes, India

Lipaglyn (saroglitazar) is approved for the treatment of hypertriglyceridaemia in type 2 diabetes.

Lipitor (Atorvastatin) – Treatment for High Cholesterol

Lipitor (Atorvastatin) is a statin class drug indicated for reducing high cholesterol levels in the blood, which helps prevent cardiovascular diseases. It is manufactured by Pfizer.

Lipitor / Torcetrapib – Combination Therapy

Under development by Pfizer, torcetrapib is a member of the cholesteryl ester transfer protein (CETP) inhibitor class of

Liptruzet (ezetimibe and atorvastatin) for the Treatment of Hyperlipidaemia

Liptruzet (ezetimibe and atorvastatin) is a combination drug indicated to reduce elevated low-density lipoprotein (LDL) cholesterol in patients suffering from hyperlipidaemia disorder.

Liraglutide – Next-Generation Antidiabetic Medication

Under development by Novo Nordisk, liraglutide is a member of a new class of antidiabetic medications called GLP-1 analo

Livmarli™ (maralixibat) for the Treatment of Cholestatic Pruritus in Alagille Syndrome

Livmarli™ (maralixibat) is the first and only approved treatment for cholestatic pruritus in patients with Alagille syndrome.

Livtencity (maribavir) for the Treatment of Post-Transplant Cytomegalovirus (CMV) Infection, USA

Livtencity™ is the first and only treatment for post-transplant cytomegalovirus infection in adult and paediatric patients.

Lixisenatide

Lixisenatide is an investigational glucagon-like peptide (GLP)-1 agonist being developed for the treatment of type 2 d

LODOCO (colchicine) for the Treatment of Cardiovascular Disease, USA

LODOCO® (colchicine) is the first FDA-approved anti-inflammatory atheroprotective cardiovascular treatment.

LODOTRA – Treatment for Rheumatoid Arthritis

Lodotra was developed utilising SkyePharma's proprietary GeoClock and GeoMatrix technologies, for which Horizon Pharma holds an exclusive worldwide license for the delivery of corticosteroids.

Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalaemia

Lokelma is an oral suspension of sodium zirconium cyclosilicate that is indicated for the treatment of patients with hyperkalaemia.

Lonsurf (trifluridine and tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer

Lonsurf (trifluridine and tipiracil) is an oral anti-cancer drug indicated for the treatment of patients with advanced metastatic colorectal cancer (mCRC) that are unresponsive to other therapies such as chemotherapy and biological therapy.

Lorbrena (lorlatinib) for ALK-Positive Metastatic Non-Small Cell Lung Cancer

Lorbrena® (lorlatinib) is an anaplastic lymphoma kinase (ALK) inhibitor indicated as a second or third-line treatment of advanced non-small cell lung cancer (NSCLC). The drug was discovered and developed by Pfizer.

Lorcaserin, Investigational Oral Anti-Obesity Drug

Lorcaserin hydrochloride (Lorcaserin) is an investigative oral treatment drug for obesity, and was discovered by Arena P

Lovenox (Enoxaparin Sodium) – Treatment for Deep Vein Thrombosis (DVT)

Lovenox (enoxaparin sodium) is an anti-thrombotic drug indicated for the treatment of deep vein thrombosis (DVT) and acute ST-segment elevation myocardial infarction (STEMI).

Lucemyra (lofexidine) for the Management of Opioid Withdrawal Symptoms

Lucemyra™ (lofexidine) is a non-opioid medication indicated for the mitigation of opioid withdrawal symptoms.

Lucentis (ranibizumab) for the Treatment of Diabetic Macular Edema (DME)

Lucentis (ranibizumab) is a monoclonal antibody indicated for the treatment of diabetic macular edema (DME). The drug is developed by Genentech, a subsidiary of Roche Group.

LUMAKRAS™ (sotorasib) for the Treatment of Non-Small Cell Lung Cancer

LUMAKRAS (sotorasib) is approved in the US, United Arab Emirates (UAE), Canada and the UK.

Lumoxiti (Moxetumomab pasudotox –tdfk) for the Treatment of Hairy Cell Leukaemia

Lumoxiti (Moxetumomab pasudotox) is an investigational anti-CD22 recombinant immunotoxin developed as a potential treatment for relapsed/refractory hairy cell leukaemia (HCL) patients previously treated with at least two lines of therapy.

LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis, US

LUPKYNIS™ (voclosporin) is a calcineurin-inhibitor immunosuppressant indicated for the treatment of adult patients with active lupus nephritis (LN).

Lurasidone – Treatment for Schizophrenia and Bipolar Disorder

Lurasidone is an atypical antipsychotic agent developed by Japan's Dainippon Sumitomo Pharma (DSP). The drug is indicat

Lutathera (lutetium Lu 177 dotatate) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumours

Lutathera® (lutetium Lu 177 dotatate) is a peptide receptor radionuclide therapy (PRRT) indicated for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.

Luxturna (voretigene neparvovec) for the Treatment of Biallelic RPE65 Mutation-Associated Retinal Dystrophy

LuxturnaTM (voretigene neparvovec) is approved for the treatment of patients with biallelic RPE65 mutation-associated retinal dystrophy.

LY2140023 – Treatment of Schizophrenia

Under development by Eli Lilly, LY2140023 is a novel investigational agent for the treatment of schizophrenia. A member

Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder

Lybalvi® is a prescription medicine indicated for the treatment of adults with schizophrenia and bipolar I disorder.

Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer

Lynparza (olaparib), discovered and developed by AstraZeneca, is the first PARP inhibitor drug approved for germline BRCA-mutated advanced ovarian cancer.

Lyrica (Pregabalin) for the Treatment of Neuropathic Pain, USA

Lyrica is a 3-substituted analogue of gamma-aminobutyric acid indicated to treat neuropathic pain.

Lyumjev (insulin lispro-aabc) for the Treatment of Type 1 and Type 2 Diabetes

Lyumjev™ (insulin lispro-aabc) is rapid-acting insulin indicated to enhance glucose control in adults with type 1 and type 2 diabetes.

M

M6G, A New Morphine Derivative For Post-Operative Pain Relief

Morphine-6-Glucuronide (M6G) is a new morphine derivative under development by biopharmaceutical company PAION. Developm

Maraviroc – Therapy for Treatment of HIV Infection

Discovered and developed by researchers at Pfizer, maraviroc is a novel treatment for infection due to the human immunod

Mavenclad (cladribine tablets) for the Treatment of Relapsing-Remitting Multiple Sclerosis

Mavenclad™ (cladribine tablets) is a selective immune reconstitution therapy indicated for the treatment of active relapsing multiple sclerosis.

MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6).

Mayzent for the Treatment of Multiple Sclerosis, US

The drug has been approved by governmental health departments in the US, Japan, Europe, and Canada.

Mekinist (Trametinib) – Treatment for Metastatic Melanoma

Mekinist (trametinib) is a mitogen-activated protein kinase (MEK) inhibitor indicated for the treatment of unresectable or metastatic melanoma in adult patients.

Menactra – Meningococcal Vaccine

Menactra vaccine is developed and manufactured by Sanofi Pasteur, the vaccines division of the Sanofi Aventis Group. The

Menveo vaccine for the prevention of invasive meningococcal disease

Menveo is an active immunisation vaccine indicated for the prevention of invasive meningococcal disease caused by sero

Merck Isentress – Emerging Therapy for Treatment of HIV Infection

Under development by Merck & Co, Isentress (raltegravir) is an experimental drug indicated for the treatment of human im

Mirapex (Pramipexole Dihydrochloride) for the Treatment of Parkinson’s Disease, USA

Mirapex is indicated to treat Parkinson’s disease (PD) symptoms and restless legs syndrome (RLS).

Monovisc (sodium hyaluronate) for the Treatment of Osteoarthritis

Monovisc (sodium hyaluronate), indicated for the treatment of Osteoarthritis (OA) of the knee, is the first US Food and Drug Administration (FDA) approved single injection made with hyaluronate from a non-animal source.

MOR103 – Antibody for the Treatment of Rheumatoid Arthritis

MOR103 is a fully human antibody indicated for the treatment of rheumatoid arthritis (RA). The drug is being developed

Motavizumab – New Biological Therapy for RSV Prevention

Developed by MedImmune (now wholly owned by AstraZeneca), motavizumab is an investigational monoclonal antibody (MAb) in

Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA

Mounjaro™ (tirzepatide) is a first-in-class GIP and GLP-1 receptor agonist for treating type 2 diabetes.

Movantik for the Treatment of Opioid-Induced Constipation

Movantik™ (naloxegol) is an opioid antagonist therapy indicated for the treatment of opioid-induced constipation in adult patients with chronic, non-cancerous pain.

Multaq

Multaq (dronedarone) is a Class III antiarrhythmic drug developed by Sanofi-Aventis (formerly Sanofi-Synthlelabo) for th

Myalepta (metreleptin) for the Treatment of Lipodystrophy

Myalepta® (metreleptin) is a recombinant human leptin analogue indicated to treat complications of congenital or acquired generalised lipodystrophy.

Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder

Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above.

Mylinax – Novel Therapy for the Treatment of

The product of a joint development programme between IVAX Corporation and Serono, Mylinax, a proprietary oral formulatio

Myobloc (rimabotulinumtoxinB) for the Treatment of Chronic Sialorrhea

Myobloc® (rimabotulinumtoxinB) is the first neurotoxin approved for the treatment of chronic sialorrhea in adults.

Myrbetriq (Mirabegron) – Treatment for Overactive Bladder (OAB)

Myrbetriq (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of the overactive bladder (OAB) condition. It was developed by Japan's Astellas Pharma.

N

Namzaric (Memantine/Donepezil) for the Treatment of Alzheimer’s Disease

Namzaric (memantine/donepezil) is the first fixed-dose combination drug approved for the treatment of moderate and severe Alzheimer's disease in the US.

Naproxcinod (HCT 3012) – COX-Inhibiting Nitric Oxide-Donator

Developed by French pharmaceutical company NicOx, naproxcinod (HCT 3012) is the first in a new class of analgesic and an

Natesto Nasal Gel for the Treatment of Men with Low Testosterone

Natesto (testosterone, formerly known as CompleoTRT) is the only FDA-approved nasal gel for treatment of adult males with conditions associated with deficiency or absence of endogenous testosterone.

Natpara® (parathyroid hormone) for the Treatment of Hypoparathyroidism

Natpara® (parathyroid hormone), a subcutaneous injection indicated for the treatment of hypoparathyroidism, was discovered and developed by NPS Pharmaceuticals that was acquired by Shire in February 2015.

Nerlynx (neratinib) for the Treatment of Breast Cancer

Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with early stage HER2-overexpressed or amplified breast cancer.

Nesina (alogliptin) for Treatment of Type 2 Diabetes Mellitus

Nesina (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor developed and marketed by Takeda Pharmaceuticals for the treatment of diabetes 2 mellitus.

Nexavar for Kidney or Liver Cancer

Nexavar is an oral anti-cancer agent that blocks cell proliferation and tumour angiogenesis. Developed by Bayer Healthcare with Onyx Pharmaceuticals, the drug obstructs the receptor tyrosine kinases – vascular endothelial growth factor receptor (VEGFR) VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR B), KIT, fms-related tyrosine kinase 3 (FLT-3) and RET – along the signalling pathways.

Nexium I.V.- Treatment of Gastroesophageal Reflux Disease

Nexium I.V. (intravenous) / esomeprazole sodium is a proton pump inhibitor manufactured and marketed by Astra Zeneca fo

Nexviazyme (avalglucosidase alfa-ngpt) for the Treatment of Late-onset Pompe Disease

Nexviazyme® (avalglucosidase alfa-ngpt) is a new therapeutic option approved for the treatment of late-onset Pompe disease.

NG2-73 – A Novel Agent For The Treatment of Insomnia

Under development by specialist pharmaceutical company, Neurogen, NG2-73 is a new, selective gamma-amino butyric acid (G

NicVAX for Nicotine Addiction

NicVAX is an investigational vaccine developed for use as an aid to treat smoking addiction and prevent smoking relaps

Ninlaro (ixazomib) for the Treatment of Multiple Myeloma

Ninlaro (ixazomib) is a proteasome inhibitor indicated for the treatment of multiple myeloma.

Northera (droxidopa) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (NOH)

Northera (droxidopa) is the world’s first approved therapy for symptomatic neurogenic orthostatic hypotension (NOH).

NOURIANZ (istradefylline) for the Treatment of Parkinson’s Disease

NOURIANZ (istradefylline) is indicated as adjunctive therapy to levodopa and carbidopa medications in adult patients with Parkinson’s disease (PD) to treat “off” episodes, caused when existing medications are ineffective and lead to an increase in PD symptoms.

Novavax Trivalent VLP Vaccine for Seasonal Influenza

Novavax's trivalent seasonal influenza virus-like particle (VLP) vaccine was developed to address the need to produce va

Noxafil (posaconazole) for the Treatment of Fungal Infections

Noxafil (posaconazole) is a triazole antifungal agent indicated for treatment of the prophylaxis of invasive Aspergillus and Candida infections.

Nucala (mepolizumab) for the Treatment of Hypereosinophilic Syndrome (HES)

Nucala® (mepolizumab) is the first biologic therapy indicated for the treatment of hypereosinophilic syndrome (HES) in adult and paediatric patients aged 12 years and older.

Nuedexta for the Treatment of Pseudobulbar Affect (PBA)

Nuedexta (dextromethorphan hydrobromide / quinidine sulfate) is a combination drug indicated for the treatment of pseudobulbar affect (PBA). The drug was developed and manufactured by Avanir Pharmaceuticals.

Nulibry™ (Fosdenopterin) for the Treatment of Molybdenum Cofactor Deficiency Type A

Nulibry™ (fosdenopterin) is the first and only US Food and Drug Administration (FDA) approved treatment indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

Nulojix – Treatment for Preventing Acute Organ Rejection Post Kidney Transplantation

Nulojix (Belatacept) was developed by Bristol Myers Squibb and is indicated to prevent the rejection of the organ in p

Nuplazid (pimavanserin) for the Treatment of Parkinson’s Disease Psychosis (PDP), USA

Nuplazid (pimavanserin) is an atypical antipsychotic drug indicated for the treatment of Parkinson’s disease psychosis (PDP).

NURTEC (Rimegepant) for the Acute Treatment of Migraine

NURTECTM (Rimegepant) is the only calcitonin gene-related peptide (CGRP) receptor antagonist indicated for acute treatment of migraine in adults.

Nuwiq, Anti-Haemophilic Factor (recombinant) for the Treatment of Haemophilia A

Nuwiq injection is the first recombinant anti-haemophilic factor (blood coagulation factor VIII) drug indicated for the treatment of patients with haemophilia A.

Nymalize (nimodipine) for the Treatment of Subarachnoid Haemorrhage (SAH)

Nymalize (nimodipine) is an oral liquid form capsule indicated to improve neurological outcomes in patients suffering from subarachnoid haemorrhage (SAH).

O

Obizur Antihemophilic Factor (recombinant) for the Treatment of Acquired Haemophilia A

Obizur antihemophilic factor (recombinant) is the first recombinant porcine FVIII indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA).

Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis

Developed by Genentech, Ocrevus (ocrelizumab) is indicated for the treatment of relapsing multiple sclerosis (MS) and primary progressive MS.

Odomzo (sonidegib) for the Treatment of Locally Advanced Basal Cell Carcinoma

Odomzo® (sonidegib) is an oral, selective smoothened (SMO) inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC). The drug was discovered and developed by Novartis.

Ofev (nintedanib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Discovered and developed by German pharmaceutical company Boehringer Ingelheim, Ofev (nintedanib) is the first and only tyrosine kinase inhibitor (TKI) to receive approval for the treatment of idiopathic pulmonary fibrosis (IPF).

Olcegepant – Novel Therapy for Acute Migraine

Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP)

OLINVYK (oliceridine) for the Treatment of Acute Pain

OLINVYK™ (oliceridine) is a new chemical agent indicated for the treatment of acute pain in adults for whom the available treatments are ineffective.

Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2 inhibitors for the treatment of moderate-to-severe active rheumatoid arthritis (RA).

Olysio (simeprevir) for the Treatment of Chronic Hepatitis C (CHC)

Olysio (simeprevir) is an antiviral drug indicated for the treatment of chronic hepatitis C (CHC) infection.

Omidria™ for Use in Cataract and Other Intraocular Lens Replacement (ILR) Procedures

Omidria (ketorolac and phenylephrine/ OMS302) is the only approved drug for intraocular use to prevent intraoperative miosis and reduce postoperative pain in cataract surgery and other intraocular lens replacement (ILR) procedures.

Omontys (peginesatide) – for Treatment of Anaemia Associated with Chronic Kidney Disease

Omontys (peginesatide) is an erythropoiesis-stimulating agent (ESA) developed for the treatment of anaemia associated with chronic kidney disease (CKD).

Onbrez Capsules – Treatment for Chronic Obstructive Pulmonary Disease

Onbrez capsules are hard capsules developed by Novartis for the treatment of chronic obstructive pulmonary disease (CO

Onfi (Clobazam) – Treatment for Lennox-Gastaut Syndrome

Onfi (clobazam) is an antiepileptic drug approved to treat seizures that are associated with Lennox-Gastaut syndrome (LGS) in patients who are aged two years and above.

ONGENTYS (opicapone) for the Treatment of Parkinson’s Disease

ONGENTYS® (opicapone) is the first and only approved catechol-O-methyltransferase (COMT) inhibitor indicated for the treatment of Parkinson's disease with off episodes, used as an adjunctive treatment to levodopa and carbidopa.

Onivyde (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer

Onivyde (MM-398 / irinotecan liposome injection) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer.

Onpattro (patisiran) for the Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Onpattro™ (patisaran) is the first-of-its-kind RNA interference (RNAi)-based drug indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

ONUREG (azacitidine) for the Treatment of Acute Myeloid Leukaemia (AML)

ONUREG® (azacitidine) is the first and only US Food and Drug Administration (FDA)-approved drug indicated for the continued treatment of acute myeloid leukaemia (AML) in adult patients.

ONZETRA Xsail for the Treatment of Migraine in Adults

ONZETRA Xsail is a Food and Drug Administration (FDA)-approved intranasal dry powder formulation developed by Avanir Pharmaceuticals.

Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma

Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in patients with a positive BRAF V600 mutation who were previously treated and made progression with Yervoy (ipilimumab).

Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Unresectable or Metastatic Melanoma, USA

Opdualag™ (nivolumab and relatlimab-rmbw) is indicated for the treatment of unresectable or metastatic melanoma.

Opsumit (Macitentan) for Treatment of Pulmonary Arterial Hypertension (PAH)

Opsumit (macitentan) is an oral dual endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH).

Opzelura (ruxolitinib) for the Treatment of Vitiligo, US

Opzelura (ruxolitinib) is the first and only topical treatment for repigmentation in vitiligo patients to have been approved by the Food and Drug Administration (FDA).

Oral-Lyn – Oral Spray Formulation of Human Insulin for Types 1 and 2 Diabetes

Oral-Lyn is an oral spray formulation of human insulin indicated for the treatment of type 1 and 2 diabetes. It is being

Orbactiv (oritavancin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Orbactiv (oritavancin) is the first and only approved antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.

Orenitram (treprostinil) for Treatment of Pulmonary Arterial Hypertension (PAH)

Orenitram (treprostinil/UT-15C) is indicated for the treatment of pulmonary arterial hypertension (PAH), in World Health Organisation (WHO) Group I patients, to improve exercise capacity.

ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer

ORGOVYX™ (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer in adult patients.

ORILISSA (elagolix) for the Treatment of Pain Associated with Endometriosis

ORILISSA (elagolix) is an oral gonadotropin-releasing hormone (GnRH) antagonist indicated for the treatment of moderate-to-severe pain associated with endometriosis.

Oritavancin – Glycopeptide Antibiotic

Oritavancin is an investigational glycopeptide antibiotic being developed by Targanta Therapeutics for the treatment of

Orkambi (lumacaftor/ivacaftor) for the Treatment of Cystic Fibrosis (CF)

Orkambi (lumacaftor/ivacaftor) is the first approved medicine to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease.

ORLADEYO (berotralstat) for the Treatment of Hereditary Angioedema (HAE), USA

ORLADEYO™ (berotralstat) is the first oral, once-daily preventive therapy indicated for hereditary angioedema (HAE).

Orserdu (elacestrant) for the Treatment of Advanced or Metastatic Breast Cancer, USA

Orserdu™ is the first endocrine therapy for ESR1-mutated advanced or metastatic breast cancer in more than two decades.

Osanetant – Novel Investigational Agent for Treatment of Schizophrenia

Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was

Otezla (apremilast) for the Treatment of Active Psoriatic Arthritis

Otezla (apremilast), developed by Celgene Corporation, is an inflammatory drug indicated for the treatment of adult patients with active psoriatic arthritis (PsA).

Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease

Oxbryta™ (voxelotor), previously known as GBT440, is the first and only FDA-approved sickle haemoglobin polymerisation inhibitor indicated for the treatment of sickle cell disease (SCD).

Oxervate (cenegermin-bkbj) to Treat Neurotrophic Keratitis, US

Oxervate™ (cenegermin-bkbj) is an ophthalmic solution indicated for the treatment of moderate-to-severe neurotrophic keratitis.

OXLUMO (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

OXLUMO™ (lumasiran) is the first small interfering ribonucleic acid (RNAi) therapeutics indicated for the treatment of primary hyperoxaluria type 1 (PH1) to reduce urinary oxalate levels in paediatric and adult patients.

Oxtellar XR for the Treatment of Partial Seizures

Oxtellar XR (oxcarbazepine/ SPN-804) is an anti-epileptic drug indicated for the treatment of partial seizures. The drug is developed, manufactured and marketed by Supernus Pharmaceuticals.

Oxytrol (oxybutynin) for the Treatment of Overactive Bladder (OAB) in Women

Oxytrol (oxybutynin) is a transdermal patch indicated for the treatment of overactive bladder in women who have symptoms of urge urinary incontinence, urgency and frequency.

Ozempic (semaglutide) for the Treatment of Type 2 Diabetes

Ozempic® (semaglutide) is a glucagon-like peptide (GLP-1) receptor agonist indicated for the treatment of Type 2 diabetes in adults.

P

Padcev (enfortumab vedotin) for the Treatment of Urothelial Cancer, USA

Padcev (enfortumab vedotin) is the first Nectin-4-directed antibody-drug conjugate approved to treat urothelial cancer.

Palynziq (pegvaliase-pqpz) for the Treatment of Phenylketonuria

Palynziq™ (pegvaliase-pqpz) is a subcutaneous infusion indicated for the treatment of adults with phenylketonuria (PKU).

Pandemrix – Adjuvanted H1N1 Influenza Vaccine

Pandemrix is an adjuvanted vaccine used in the prevention of the H1N1 (swine flu) virus infection and has been developed

Panflu.1 – Single-Shot Vaccine Against H1N1 Influenza

Developed by Sinovec Biotech to provide protection against the H1N1 virus, also known as swine flu, Panflu.1 is a single

Parsabiv™ (etelcalcetide) for the Treatment of Secondary Hyperparathyroidism (SHPT)

Parsabiv™ (etelcalcetide) is an intravenous injectable calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) that were previously treated with haemodialysis.

Paxil – SSRI for the Treatment of Major Depressive Disorders

Paxil (paroxetine hydrochloride) was first developed in 1975 by a Danish company called Ferrosan. During 1980 Ferrosan s

Paxlovid (nirmatrelvir and ritonavir) for the Treatment of COVID-19

Paxlovid™ is the first FDA-approved oral antiviral treatment for mild to moderate COVID-19 in adult and paediatric patients.

Pemazyre™ (pemigatinib) for the Treatment of Cholangiocarcinoma

Pemazyre™ (pemigatinib) is the first and only US Food and Drug Administration (FDA)-approved kinase inhibitor indicated for the treatment of cholangiocarcinoma.

PEPAXTO® (melphalan flufenamide) for the Treatment of Multiple Myeloma

PEPAXTO® (melphalan flufenamide) is a first-in-class peptide-drug conjugate indicated in combination with the glucocorticoid dexamethasone for the treatment of relapsed or refractory (r/r) multiple myeloma in adult patients.

Pertuzumab – Treatment / Therapy for Breast Cancer

Roche / Genentech's Perjeta (Pertuzumab) is a humanised monoclonal antibody (MAb) to the HER2 receptor for the treatment of advanced breast cancer.

Phenserine – Next Generation AChE Inhibitor

Axonyx, a US biopharmaceutical company that focuses on treatments for dementia, developed phenserine as a next-generatio

Pifeltro (doravirine) for the Treatment of HIV-1 Infection

Pifeltro (doravirine) is indicated for the treatment of adult patients with Human Immunodeficiency Virus-1 (HIV-1) infection.

Piqray (alpelisib) for the Treatment of Advanced Breast Cancer

Piqray® (alpelisib) is a kinase inhibitor indicated for the treatment of hormone receptor (HR) positive or HER2-negative advanced breast cancer with PIK3CA mutation in men and post-menopausal women.

Pirfenidone – Treatment for Idiopathic Pulmonary Fibrosis

Pirfenidone is a drug indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring and thickening of lungs.

Plavix (Clopidogrel Bisulfate) – Treatment for Acute Coronary Syndrome

Plavix (clopidogrel bisulfate) is a thienopyridine class inhibitor indicated for the treatment of acute coronary syndrome (ACS).

Plectasin NZ2114 – Novel Microbial Agent

Under development by Novozymes A/S, the Danish biotechnology company, plectasin NZ2114 is a novel antimicrobial peptide.

Plegridy (peginterferon beta-1a) for the Treatment of Relapsing Multiple Sclerosis (RMS)

Plegridy (peginterferon beta-1a) is the only pegylated beta interferon approved for the treatment of relapsing multiple sclerosis (RMS). The drug was discovered and developed by Biogen Idec.

Pluvicto for the treatment of metastatic castration-resistant prostate cancer

Pluvicto™ is the first FDA-approved targeted radioligand therapy for PSMA+ metastatic, castration-resistant prostate cancer.

Polivy (polatuzumab vedotin) for the Treatment of Diffuse Large B-cell Lymphoma

Polivy™ (polatuzumab vedotin-piiq) is an antibody-drug conjugate indicated for the third-line treatment of adults with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

Pomalyst (Pomalidomide) for the Treatment of Multiple Myeloma

Pomalyst (pomalidomide) is an anti-angiogenic drug developed by Celgene Corporation for the treatment of multiple myeloma in patients who have received two prior therapies.

PONVORY (ponesimod) for the Treatment of Multiple Sclerosis

PONVORY™ (ponesimod) is an oral disease-modifying therapy approved for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).

Portrazza (necitumumab) for the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Portrazza (necitumumab) is a recombinant human lgG1 monoclonal antibody developed by Eli Lilly, for the treatment of metastatic squamous non-small cell lung cancer (NSCLC).

POSLUMA (flotufolastat F 18) PET Imaging Agent for Prostate Cancer, USA

POSLUMA® is the first FDA-approved radio-hybrid PSMA-targeted agent for PET imaging of prostate cancer in adults.

Poteligeo for the Treatment of Mycosis Fungoides and Sezary Syndrome

Poteligeo® (mogamulizumab-kpkc) is a monoclonal antibody (mAb) indicated for the treatment of mycosis fungoides and Sézary syndrome in adults.

Pradaxa (dabigatran etexilate) – Oral Direct Thrombin Inhibitor

Pradaxa (dabigatran etexilate) is an oral anticoagulant under development by Boehringer Ingelheim. Its primary indicatio

Praluent (alirocumab) for the Treatment of Hypercholesterolemia

Praluent (alirocumab) is an investigational therapy injection intended for the treatment of patients with hypercholesterolemia.

Prasugrel, Investigational Antiplatelet Agent by Daiichi Sankyo and Lilly

Originally discovered by Sankyo and Ube Industries, prasugrel is now the product of a co-development programme between D

Prexige – COX-2 Inhibitor

Prexige (lumiracoxib) is an innovative COX-2 inhibitor developed by Novartis for the relief of pain and inflammation ass

Prezcobix™ (darunavir/cobicistat) for the Treatment of HIV-1

Prezcobix™ (darunavir / cobicistat), discovered and developed by Janssen Therapeutics, is a fixed-dose antiretroviral combination tablet indicated for the treatment of human immunodeficiency virus (HIV-1) infection.

PRIORIX for the Prevention of Measles, Mumps and Rubella, USA

The PRIORIX vaccine is approved for the prevention of measles, mumps and rubella (MMR) in people aged 12 months and older.

Procysbi (cysteamine bitartrate) for the Treatment of Nephropathic Cystinosis

Procysbi (cysteamine bitartrate) is a delayed-release capsule indicated for the treatment of nephropathic cystinosis. The drug was discovered and developed by Raptor Pharmaceutical (Raptor).

Prolia (Denosumab) – Therapy for Prevention and Treatment of Osteoporosis

Amgen's prolia (denosumab) is a biological therapy developed for the prevention and treatment of osteoporosis and other

Promacta (eltrombopag) for the Treatment of Severe Aplastic Anaemia (SAA)

Promacta (eltrombopag) is the first-in-class treatment indicated for patients with severe aplastic anaemia (SAA) immunosuppressive therapy (IST) was proven ineffective for.

Provenge – Treatment for Advanced Prostate Cancer

Provenge (sipuleucel-T) is an autologous cellular immunotherapy used intravenously in the form of infusion for the treatment of men with advanced prostate cancer.

PSI-7977 for Treatment of Chronic Hepatitis C

PSI-7977 is indicated for the treatment of chronic Hepatitis C-virus (HCV) infection. The investigational drug is being

Q

QINLOCK (ripretinib) for the Treatment of Gastrointestinal Stromal Tumour

QINLOCK™ (ripretinib) is indicated as a fourth-line treatment for advanced gastrointestinal stromal tumour (GIST) in adult patients who have completed previous treatment with three or more kinase inhibitors, including imatinib.

Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes

Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes.

Quillivant XR (methylphenidate) for Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Quillivant XR (methylphenidate) is a psychostimulant drug indicated for Attention Deficit Hyperactivity Disorder (ADHD).

Quizartinib Indicated for the Treatment of FLT3-ITD AML

Quizartinib is an investigational oral selective FLT3 inhibitor being developed for the treatment of adult patients with acute myeloid leukaemia (AML) having FLT3 internal tandem duplication (ITD) mutation.

QUVIVIQ (daridorexant) for the Treatment of Insomnia, USA

QUVIVIQ™ (daridorexant) is a new treatment option developed by Idorsia Pharmaceuticals for adult patients with insomnia.

R

RAD001 – Anti-Cancer Therapy, Anti-neoplastic agent by Novartis

Afinitor (everolimus), formerly known as RAD001, is a macrolide antibiotic derived from rapamycin that is being investig

Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Rapamune (sirolimus) for the Treatment of Lymphangioleiomyomatosis (LAM)

Rapamune (sirolimus), an immunosuppressive agent, is the first approved medicine in the US for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that affects the lungs, kidneys and the lymphatic system.

Rapiacta (peramivir) – Neuraminidase Inhibitor for Treatment of Influenza

Rapiacta (peramivir) as is a neuraminidase inhibitor discovered and developed by BioCryst Pharmaceuticals for the treatm

Rasagiline – Second-Generation MAO-B Inhibitor for the Treatment of Parkinson’s Disease

Azilect® (rasagiline) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease (PD).

Rasilez – Innovative Treatment for Hypertension

The product of a joint development programme between Swiss companies Speedel and Novartis, Rasilez (aliskiren) is an ora

Ravicti (glycerol phenylbutyrate) for Treatment of Urea Cycle Disorders (UCD)

Ravicti (glycerol phenylbutyrate) is indicated for the treatment of Urea Cycle Disorders (UCD) in adults and paediatric patients aged two and above.

REBLOZYL® (luspatercept-aamt) for the Treatment of Anaemia Associated with Beta-Thalassemia

REBLOZYL® (luspatercept-aamt) is a novel erythroid maturation agent (EMA) approved to treat anaemia associated with beta-thalassemia in adult patients who require regular red blood cell (RBC) transfusions.

REGEN-COV (Casirivimab with Imdevimab) for the Treatment of Mild to Moderate Covid-19

REGEN-COV™ (casirivimab with imdevimab) is an investigational monoclonal antibody cocktail authorised for the treatment of mild to moderate Covid-19 in adults and paediatric patients aged 12 years and older who are infected with SARS-COV-2 and are at high risk of progression to severe Covid-19.

Relyvrio (sodium phenylbutyrate/taurursodiol) to Treat Amyotrophic Lateral Sclerosis, USA

Relyvrio is an oral, fixed-dose combination therapy for amyotrophic lateral sclerosis (ALS) in adults.

Rember – Novel Therapy for Alzheimer’s Disease

Rember (methylthioninium chloride) is a potential disease-modifying therapy for Alzheimer's disease that is under develo

Remdesivir for Potential Treatment of Covid-19

Remdesivir is an investigational antiviral drug being developed by Gilead Sciences for the treatment of COVID-19, a coronavirus disease, and Ebola virus infection.

Repatha (evolocumab) for the Treatment of Heterozygous and Homozygous Familial Hypercholesterolaemia

Repatha (evolocumab), developed by Amgen, is indicated for heterozygous familial hypercholesterolaemia (HeFH).

Restanza

Restanza (cethromycin) is a second-generation ketolide, once-a-day oral antibiotic that is under review for approval by

Retevmo (selpercatinib) for the Treatment of RET-Driven Cancers

Retevmo™ (selpercatinib) is the first therapy approved for the treatment of three rearranged during transfection (RET)-driven cancer indications.

Revatio (Sildenafil) – Treatment for Pulmonary Arterial Hypertension

Revatio is an approved formulation developed by Pfizer for the treatment of pulmonary arterial hypertension. The drug w

Revcovi for the Treatment of ADA-SCID

Revcovi (elapegademase-lvlr) is a PEGylated recombinant adenosine deaminase (rADA) enzyme indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in paediatric and adult patients.

Revlimid (Lenalidomide) for the Treatment of Mantle Cell Lymphoma (MCL)

Revlimid (lenalidomide) oral capsules are indicated for the treatment of Mantle Cell Lymphoma (MCL).

Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia

Rexulti (brexpiprazole) is a newly-discovered psychotropic compound indicated as an add-on therapy for major depressive disorder (MDD) and as a treatment for schizophrenia.

Rezular – Oral Treatment for IBS

Developed by AGI Therapeutics, Rezular (arverapamil) is an orally administered triple-action intestinal regulator indica

REZUROCK™ (belumosudil) for the Treatment of Chronic Graft-Versus-Host Disease

REZUROCK™ (belumosudil) is an oral kinase inhibitor indicated for the treatment of chronic graft-versus-host disease (cGVHD) in patients aged 12 years and older who have received at least two failed previous lines of alternative systemic therapy.

RiaSTAP – Treatment for Congenital Fibrinogen Deficiency (CFD)

CSL Behring's RiaSTAP is a lyophilised fibrinogen concentrate targeted at the treatment of congenital fibrinogen deficiency (CFD). It can also be used for the treatment of afibrinogenemia and hypofibrinogenemia.

Rifapentine

Rifapentine is an antibiotic drug developed by Sanofi-aventis for treating tuberculosis (TB). It is marketed under the

Rinvoq (upadacitinib) for the Treatment of Active Crohn’s Disease, USA

Rinvoq is approved in the US and Europe for active Crohn’s disease.

Rituxan (Rituximab)

Rituxan (Rituximab) is a monoclonal antibody indicated for treating advanced follicular lymphoma. The drug was developed

Rixubis (coagulation factor IX (recombinant)) for the Treatment of Haemophilia B

Rixubis [coagulation factor IX (recombinant)] is indicated for the control and prevention of bleeding episodes and perioperative management in the treatment of adult patients suffering from haemophilia B.

Rozlytrek (entrectinib) for the Treatment of Solid Cancerous Tumours

Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced solid tumours in adult and paediatric patients.

Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer

Poly adenosine diphosphate ribose polymerase (PARP) inhibitor Rubraca® (rucaparib) is indicated for the treatment of breast cancer susceptibility gene (BRCA) mutation-linked advanced ovarian cancer.

Ruconest for Treatment of Hereditary Angioedema (HAE)

Ruconest (C1 Esterase Inhibitor [Recombinant]) is a recombinant approved for treatment of acute angioedema attacks in patients suffering from hereditary angioedema (HAE).

Rukobia (fostemsavir) for the Treatment of HIV

Rukobia (fostemsavir) is an antiretroviral drug, developed by ViiV Healthcare, for the treatment of HIV-1 infection in adult patients.

Rupintrivir (AG7088)

Agouron Pharmaceuticals, a subsidiary of Pfizer, has pioneered the development of rupintrivir (AG7088), an experimental treatment for the common cold.

Ruzurgi (amifampridine) for the treatment of LEMS

Ruzurgi (amifampridine) is approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in paediatric patients.

Rybelsus (Semaglutide) for the Treatment of Type 2 Diabetes

Rybelsus® (semaglutide) is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes in adult patients.

RYBREVANT (amivantamab-vmjw) for the Treatment of Non-Small Cell Lung Cancer

Rybrevant (amivantamab-vmjw) is the first fully-human bispecific antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has advanced on or after platinum-based chemotherapy.

Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis

Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis (SM) indications.

Rylaze™ (asparaginase erwinia chrysanthemi (recombinant) rywn)

Rylaze (asparaginase erwinia chrysanthemi (recombinant) rywn), formerly known as JZP458, is an asparagine-specific enzyme approved for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in certain adult and paediatric patients.

S

Sabril (Vigabatrin) – Treatment for Refractory Complex Partial Seizures and IS

Sabril (vigabatrin) is an antiepileptic drug indicated for the treatment of refractory complex partial seizures (CPS) and infantile spasms (IS). It was developed by Ovation Pharmaceuticals, which was later acquired by Lundbeck.

Saphnelo (Anifrolumab-fnia) for the Treatment of Systemic Lupus Erythematosus

Saphnelo is the only novel therapy approved for systemic lupus erythematosus (SLE) in more than a decade.

Sarclisa (isatuximab-irfc) for the Treatment of Multiple Myeloma

Sarclisa® (isatuximab-irfc) is a monoclonal antibody in combination with pomalidomide and dexamethasone (pom-dex) indicated for the treatment of multiple myeloma.

Sativex – Investigational Cannabis-Based treatment for Pain and Multiple Sclerosis

Developed by GW Pharmaceuticals, Sativex is a whole plant medicinal cannabis extract indicated for the relief of multiple sclerosis (MS) symptoms and the treatment of severe neuropathic-related cancer pain.

Saxagliptin – Treatment for Type 2 Diabetes

The product of a joint development programme between AstraZeneca and Bristol-Myers Squibb, saxagliptin is a member of a

Saxenda (liraglutide) for the Treatment of Obesity, US

Saxenda is a GLP-1 receptor agonist to treat obesity in adolescents with a 60kg body weight and an initial BMI of 30kg/m².

Scemblix (asciminib) for the Treatment of Chronic Myeloid Leukaemia

Scemblix (asciminib) is a first-in-class STAMP inhibitor indicated for treating chronic myeloid leukaemia (CML) in adult patients.

Secuado (asenapine) for the Treatment of Schizophrenia

Secuado® (asenapine) is an atypical anti-psychotic drug approved for the treatment of schizophrenia in adult patients. It is the first drug approved as transdermal patch formulation for schizophrenia treatment in the US.

Selincro (nalmefene) – Treatment for Alcohol Dependence

Selincro (nalmefene) is an injected drug for the treatment of alcohol dependence.

Semagacestat – Gamma Secretase Inhibitor for Alzheimer’s Disease

Semagacestat (LY-450139) was a gamma secretase inhibitor being developed as a treatment for Alzheimer's disease by Eli

Seroquel – Treatment for Major Depressive Disorder (MDD)

Seroquel (quetiapine fumarate) is an anti-psychotic drug indicated as an add-on treatment for patients suffering from

SF1126 –

SF1126 is indicated for treating chronic lymphocytic leukaemia (CLL). The drug is being developed by US-based Semafore

Shingrix (herpes zoster subunit vaccine) for the Prevention of Shingles

Shingrix is a recombinant subunit shingles vaccine that was discovered and developed by GlaxoSmithKline (GSK).

Signifor (Pasireotide) – Treatment for Cushing’s Disease

Signifor (SOM230 / Pasireotide) is a somatostatin analogue indicated for the treatment of patients with Cushing's disease for whom surgery has failed. The drug is developed and manufactured by Novartis.

Siklos (hydroxyurea) for the Treatment of Children with Sickle Cell Anaemia

Siklos® is an orally administered tablet form of hydroxyurea that is indicated for the treatment of sickle-cell anaemia in paediatric patients aged two years and older.

Silenor (doxepin) for the Treatment of Insomnia

Silenor (doxepin) is a tricyclic antidepressant indicated for the treatment of insomnia. It was developed by Somaxon Pharmaceuticals.
In March 2010, the US Food and Drug Administration (FDA) approved Silenor for the treatment of insomnia characterised by difficulty with sleep maintenance.

Simbrinza (brinzolamide/brimonidine tartrate) for the Reduction of Elevated Intraocular Pressure

Simbrinza (brinzolamide/brimonidine tartrate) is a carbonic anhydrase inhibitor developed by Alcon, a division of Novartis.

Simponi (Golimumab) – Treatment for Ulcerative Colitis (UC)

Simponi (golimumab) is a subcutaneous injection for the treatment of adult patients living with ulcerative colitis (UC). The drug was discovered and developed by Janssen Biotech.

SIMPONI ARIA (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)

SIMPONI ARIA® (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody.

Sirturo (bedaquiline) for Treatment of Pulmonary Multi-Drug Resistant Tuberculosis (TB)

Sirturo (bedaquiline) was developed by Janssen Therapeutics, a division of Janssen Products. It is indicated for the treatment of multi-drug resistant tuberculosis (MDR-TB).

Sitavig (Acyclovir) – Treatment for Herpes Labialis

Sitavig (acyclovir) is a muco-adhesive buccal tablet indicated for the treatment of recurring Herpes Labialis. The drug is manufactured and marketed by BioAlliance Pharma.

Sivextro for Treatment of Acute Bacterial Skin and Skin Structure Infections

Sivextro (tedizolid phosphate) is an oxazolidinone class antibacterial drug indicated for treatment of adult patients infected with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

Skyrizi (risankizumab-rzaa) for the Treatment of Plaque Psoriasis, USA

Skyrizi® is an interleukin-23 inhibitor indicated to treat plaque psoriasis, active psoriatic arthritis and Crohn’s disease.

Soliqua 100/33 for the Treatment of Type 2 Diabetes

Developed by Sanofi, Soliqua 100/33 (insulin glargine & Lixisenatide injection) is indicated for the treatment of Type 2 diabetes.

Soliris for the Treatment for PNH, aHUS, gMG and NMOSD

Soliris is a first-in-class terminal complement inhibitor approved for the treatment of PNH, aHUS, gMG and NMOSD.

Solithera (solithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia

Solithera (solithromycin) is a next-generation macrolide antibiotic developed by Cempra as a treatment for community-acquired bacterial pneumonia.

Solosec (secnidazole) for the Treatment of Bacterial Vaginosis and Trichomoniasis

Solosec® (secnidazole) is a next-generation antibiotic indicated for the treatment of bacterial vaginosis and trichomoniasis.

Sotagliflozin for the Treatment of Heart Failure, US

Sotagliflozin is a once-daily oral drug indicated to reduce the risk of cardiovascular death in adults.

Sotyktu (deucravacitinib) to Treat Moderate to Severe Plaque Psoriasis, USA

Sotyktu (deucravacitinib) is the first oral TYK2 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis.

Sovaldi (sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

Sovaldi (sofosbuvir), developed by Gilead Sciences (Gilead), is an oral nucleotide analog inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection.

Spevigo (Spesolimab-sbzo) to Treat Generalised Pustular Psoriasis Flares, USA

Spevigo (spesolimab-sbzo) is the first approved treatment for generalised pustular psoriasis flares in adults.

Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA)

Spinraza™ (nusinersen) is an anti-sense oligonucleotide indicated for treatment of spinal muscular atrophy (SMA) in paediatric and adult patients.

Spiriva – Treatment for Chronic Obstructive Pulmonary Disease

Spiriva is an anticholinergic drug targeted at chronic obstructive pulmonary disease (COPD). It contains tiotropium bromide as the active ingredient.

Spritam (levetiracetam) for the Treatment of Epilepsy

Spritam (levetiracetam) is an adjunctive therapy indicated for the treatment of seizures in patients with epilepsy, the fourth most common neurological disorder affecting people of all age groups.

Steglatro (ertugliflozin) for the Treatment of Type 2 Diabetes

Steglatro™ (ertugliflozin) is a combination drug indicated for the improvement of glycaemic control in adult patients with Type 2 diabetes mellitus.

Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn’s Disease

Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease.

Stimufend (pegfilgrastim-fpgk) for the Treatment of Febrile Neutropenia, USA

Stimufend® (pegfilgrastim-fpgk) is a biosimilar to Neulasta® for use in patients at risk for febrile neutropenia.

Stimuvax – Investigational Therapeutic Cancer Vaccine

Stimuvax, formerly known as BLP25 liposome vaccine (L-BLP25), is an investigational therapeutic vaccine being developed to provide immunity against the cancer cells that over express Mucin 1 (MUC-1), a glycoprotein antigen

Stiolto Respimat for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Stiolto Respimat (tiotropium bromide and olodaterol), an oral inhalation spray indicated for the treatment of chronic obstructive pulmonary disease (COPD), is manufactured by Boehringer Ingelheim Pharmaceuticals, the US subsidiary of Boehringer Ingelheim Corp.

Stivarga (Regorafenib) for Treating Metastatic Colorectal Cancer (mCRC)

Stivarga (Regorafenib) is an oral multikinase inhibitor developed by Bayer HealthCare for the treatment of metastatic colorectal cancer (mCRC).

Strensiq (asfotase alfa) for the Treatment of Hypophosphatasia

Strensiq (asfotase alfa) is the first enzyme replacement therapy (ERT) approved in the US for the treatment of perinatal / infantile and juvenile-onset hypophosphatasia (HPP), which is a life-threatening and ultra-rare metabolic disorder.

Stribild – A Single Tablet Regimen for the Treatment of HIV-1

Stribild is a combination of four compounds; elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The drug is indicated for the treatment of HIV-1 infection in adults who have never received antiretroviral treatment for the disease.

Striverdi Respimat for the Maintenance Treatment of COPD

Striverdi Respimat (olodaterol) is an inhalation spray indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and / or emphysema.

Sublocade™ for the Treatment of Opioid Use Disorder

Sublocade™ (buprenorphine extended-release) is a partial agonist indicated for the treatment of moderate-to-severe opioid use disorder (OUD) in adults.

SUN-101/eFlow for the Treatment of Chronic Obstructive Pulmonary Disease

SUN-101 (Glycopyrrolate) is an inhalation solution developed by Sunovion Pharmaceuticals as a treatment for patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Sunlenca (Lenacapavir) for the Treatment of HIV-1 Infection, USA

Sunlenca (lenacapavir) is a first-in-class, long-acting HIV capsid inhibitor approved for the treatment of HIV-1 infection.

Surfaxin (Lucinactant) – Treatment for Preventing Infant RDS

Surfaxin (Lucinactant) is a non-pyrogenic pulmonary surfactant used for the prevention of respiratory distress syndrome (RDS) in premature infants.

Sustiva (Efavirenz) – Treatment for HIV-1 Infected Paediatric Patients

Sustiva (efavirenz) is an antiretroviral indicated for the treatment of paediatric patients with the HIV-1 infection.

Susvimo (ranibizumab) for Treating Wet Age‑related Macular Degeneration

Susvimo™ (ranibizumab) is a VEGF inhibitor indicated for the treatment of neovascular age-related macular degeneration (nAMD).

Sutent (Sunitinib Malate) – Treatment for Pancreatic Neuroendocrine Tumours

Sutent (sunitinib malate) is an oral multikinase inhibitor which is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumours (NET).

Sycrest (asenapine) – Treatment for Bipolar I Disorder

Sycrest (asenapine) is an antipsychotic medicine indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder. The drug was developed by Merck.

Syfovre (pegcetacoplan) for the Treatment of Geographic Atrophy, USA

Syfovre™ is the first FDA-approved treatment for geographic atrophy, an advanced form of age-related macular degeneration.

Sylvant (siltuximab) for the Treatment of Multicentric Castleman’s Disease

Sylvant (siltuximab) is indicated for the treatment of patients with multi-centric Castleman’s disease (MCD) in the US.

Symbicort (budesonide and formoterol) for the Treatment of Asthma

Symbicort (budesonide and formoterol) is an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) indicated for the treatment of asthma in paediatric patients aged between six and 12 years. The drug was discovered and developed by AstraZeneca.

Symdeko (tezacaftor/ivacaftor and ivacaftor) for the Treatment of Cystic Fibrosis

Symdeko™ (tezacaftor/ivacaftor and ivacaftor) is a combination drug indicated for the treatment  of cystic fibrosis (CF) in people aged 12 years and above.

Synribo (Omacetaxine Mepesuccinate) for Treating Chronic Myeloid Leukaemia

Synribo (Omacetaxine Mepesuccinate) is a subcutaneously injected drug developed by Teva Oncology, a division of Teva Pharmaceutical Industries, based in the US. The drug is indicated for the treatment of patients with chronic myelogenous leukaemia (CML) in both chronic and accelerated phases.

T

T-705 – Antiviral Drug for Influenza by Toyama Chemical of Japan

T-705 is a novel oral agent indicated for the treatment of influenza that is under development by Toyama Chemical of Jap

Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Tabrecta™ (capmatinib) is the first US Food and Drug Administration (FDA)-approved therapy for the treatment of adult patients diagnosed with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that results in mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping.

Tafinlar (Dabrafenib) – Treatment for Metastatic Melanoma

Tafinlar (dabrafenib) is a single-agent oral treatment indicated for the treatment of unresectable or metastatic melanoma in adult patients.

Tagrisso (osimertinib) For the Treatment of EGFR mutation in Non-Small Cell Lung Cancer

Tagrisso (osimertinib) is a once-daily tablet developed by AstraZeneca for the treatment of metastatic epidermal growth factor receptor (EGFR) T790M mutation associated with non-small cell lung cancer (NSCLC).

Takhzyro (lanadelumab-flyo) for the Prevention of Hereditary Angioedema

Takhzyro (lanadelumab-flyo) is indicated for the preventive treatment of hereditary angioedema (HAE) in patients aged 12 years and older.

Taltz (ixekizumab) for the Treatment of Non-Radiographic Axial Spondyloarthritis

Taltz® (ixekizumab) is the first humanised interleukin (IL)-17A antagonist therapy approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective inflammation signs.

Talzenna (talazoparib) for the Treatment of Advanced Breast Cancer

Talzenna™ (talazoparib) is an inhibitor of the poly adenosine diphosphate (ADP) ribose polymerase (PARP) enzyme that is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) negative breast cancer in adult patients with the BRCA-mutated (gBRCAm) gene.

Tamiflu – Oral Anti-Viral Treatment Agent

Tamiflu or oseltamivir is a prescription drug used for prophylaxis and treatment of flu caused by influenza virus types A (H1N1) and B.

Tanzeum (albiglutide) for Treatment of Type 2 Diabetes

Tanzeum (albiglutide), developed by GlaxoSmithKline (GSK), is a GLP-1 receptor agonist indicated for treatment of type 2 diabetes.

Taranabant CB1 Receptor Inverse Agonist for Management of Obe

Taranabant is a highly selective cannabinoid-1 (CB1) receptor inverse agonist developed by Merck & Co for the treatment

Tarceva Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer

Tarceva (erlotinib) is an oral anti-cancer drug developed by OSI Pharmaceuticals, Genentech and Roche. It is a member of

Tasigna (Nilotinib)

Tasigna (nilotinib) is indicated for treating Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML). Th

TAVALISSE (fostamatinib disodium hexahydrate) for the Treatment of Chronic Immune Thrombocytopenia

TAVALISSE™ is a twice-daily regimen indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment.

Tavneos (avacopan) for the Treatment of ANCA-Associated Vasculitis

Tavneos (avacopan) is the first FDA-approved oral selective complement 5a receptor inhibitor drug for ANCA-associated vasculitis.

Tazverik (tazemetostat) for the Treatment of Epithelioid Sarcoma

Tazverik is the first approved treatment for metastatic/locally advanced epithelioid sarcoma in patients aged 16 years and older.

TB402 – Treatment of VTE and AF

The product of a co-development programme between ThromboGenics, a Belgian biotechnology company, and BioInvent Internat

TBRIA (calcitonin-salmon) for the Treatment of Postmenopausal Osteoporosis

TBRIA (calcitonin-salmon [rDNA origin] delayed release tablet) is the first oral recombinant salmon calcitonin, developed by Tarsa Therapeutics, for the treatment of postmenopausal osteoporosis.

Tecartus (brexucabtagene autoleucel) for the Treatment of Mantle Cell Lymphoma (MCL)

Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19) chimeric antigen receptor (CAR) T-cell therapy is the first and only approved cell-based gene therapy for the treatment of mantle cell lymphoma (MCL).

Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Tecentriq® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1.

Tecfidera (Dimethyl Fumarate), Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS)

Tecfidera (BG-12/Dimethyl Fumarate) is a first-line oral treatment indicated for patients with relapsing-remitting multiple sclerosis (RRMS). The drug was developed by Biogen Idec.

Technivie (Ombitasvir, Paritaprevir, Ritonavir) for the Treatment of Genotype 4 Chronic Hepatitis C

Technivie (ombitasvir, paritaprevir and ritonavir) is the first direct-acting antiviral drug approved for the treatment of genotype 4 (GT4) chronic hepatitis C virus (HCV) infection in the US.

Tegsedi for the Treatment of Polyneuropathy of hATTR Amyloidosis

Tegsedi™ (inotersen) is an anti-sense oligonucleotide indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients.

Telbivudine – Investigational Drug

The product of a joint collaborative programme between Idenix Pharmaceuticals and Novartis Pharma, telbivudine (oral L-d

Tepmetko (tepotinib) for the Treatment of Non-Small Cell Lung Cancer

Tepmetko (tepotinib) is an oral kinase inhibitor approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). It is the first and only US Food and Drug Administration (FDA) approved mesenchymal-epithelial transition (MET) inhibitor with once-daily oral dosing.

Terlivaz (terlipressin) for the Treatment of Hepatorenal Syndrome (HRS), USA

Terlivaz (terlipressin) is the first and only approved treatment of hepatorenal syndrome (HRS) in adults.

Tesmilifene – Chemopotentiator for Cancer

Tesmilifene is a small molecule chemopotentiator under development by YM BioSciences, a Candian pharmaceutical company t

Tesofensine Anti-Obesity Medication

Under development by NeuroSearch, a Danish pharmaceutical company, tesofensine is a novel treatment for obesity. A serot

Tezspire (tezepelumab-ekko) for the Treatment of Severe Asthma, USA

Tezspire (tezepelumab-ekko) is the first and only biologic indicated as an add-on maintenance treatment for severe asthma.

TIBSOVO (ivosidenib) for Treating Relapsed or Refractory AML and Advanced Cholangiocarcinoma, US

TIBSOVO® (ivosidenib) is the first approved targeted therapy for patients with IDH1-mutated advanced cholangiocarcinoma.

TIGLUTIK (Riluzole) for the Treatment of Amyotrophic Lateral Sclerosis

TIGLUTIK (Riluzole) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer

Tivdak (tisotumab vedotin-tftv) is the first and only approved antibody-drug conjugate to treat adults with cervical cancer.

Tivicay (Dolutegravir) for the Treatment of HIV-1 Infection

Tivicay (dolutegravir) is an integrase inhibitor indicated for the treatment of the HIV-1 infection in adults and children aged 12 years and above.

Tivorbex (indomethacin) for the Treatment of Acute Pain

Tivorbex (indomethacin) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults.

Toujeo for the Treatment of Type 1 and Type 2 Diabetes

Toujeo (insulin glargine [rDNA origin]) is an insulin injection approved for the treatment of type 1 and type 2 diabetes to improve glycaemic control in adult patients.

TRA-SCH-530348

TRA-SCH 530348 is an oral antiplatelet drug under development by Schering-Plough for the treatment and prevention of ath

Tradjenta Indicated for the Treatment of Type II Diabetes

Linagliptin (BI-1356), which is being marketed under the trade name Tradjenta®, is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor drug for the treatment of type 2 diabetes.

Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics.

Trastuzumab –

Trastuzumab, indicated for the treatment of recurrent gastric cancer with a high concentration of HER2 (human epiderma

Tremfya (guselkumab) for the Treatment of Plaque Psoriasis

Tremfya™ (guselkumab) is a biologic approved for the treatment moderate-to-severe plaque psoriasis in adults.

Tresiba (insulin degludec) for the Treatment of Type 1 and Type 2 Diabetes

Tresiba (insulin degludec) is the first, long-acting, human insulin indicated for the treatment of Type 1 and Type 2 diabetes. The drug was discovered and developed by Novo Nordisk.

Tretten for the Treatment of Congenital Factor XIII Deficiency

Tretten is the world’s first recombinant treatment available for the prevention of bleeding in adults and children suffering from congenital factor XIII (FXIII) A-subunit deficiency.

Treximet – Next-Generation Treatment for Migraine

The product of a joint development programme between US drug development company Pozen and GSK, Treximet is a novel comb

TRIKAFTA (elexacaftor, ivacaftor and tezacaftor) for the Treatment of Cystic Fibrosis

TRIKAFTA is the first triple combination therapy containing elexacaftor, ivacaftor, and tezacaftor indicated for the treatment of cystic fibrosis (CF) in people aged 12 years and above and having a F508del mutation and one minimal function mutation.

Triumeq (dolutegravir/abacavir/lamivudine) for the Treatment of HIV

Triumeq (dolutegravir/abacavir/lamivudine) is an investigational drug indicated for the treatment of adult and adolescent patients (minimum age of 12 years and with a minimum weight of 40kg) affected with Human Immunodeficiency Virus (HIV).

Trobalt / Potiga – Treatment for Partial-Onset Seizure

Trobalt (ezogabine / retigabine) is indicated for the treatment of partial-onset epileptic seizures in patients aged more than 18 years old.

Trodelvy (sacituzumab govitecan) for the Treatment of Advanced Triple-Negative Breast Cancer

Trodelvy (sacituzumab govitecan-hziy) is the first and the only approved antibody-drug conjugate for the treatment of advanced triple-negative breast cancer (TNBC) in adult patients.

Trofinetide for the Treatment of Rett Syndrome, US

Daybue is the first and only drug approved for the treatment of Rett syndrome, a rare neurodevelopmental disorder.

Trogarzo (ibalizumab-uiyk) for the Treatment of Multidrug-Resistant HIV-1 Infection

Trogarzo™ is indicated for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced patients.

Trulance™ (Plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC)

Trulance™ (Plecanatide) is a guanylate cyclase-C (GC-C) agonist indicated for the treatment of adult patients with chronic idiopathic constipation (CIC).

Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes

Trulicity (dulaglutide) is a glucagon-like peptide 1 receptor agonist (GLP-1 agonist) indicated for the treatment of adults with type 2 diabetes. The drug was discovered and developed by Eli Lilly and Company.

Trumenba Vaccine for Prevention of Meningococcal Meningitis B Disease

Trumenba is a vaccine licenced in the US for the prevention of invasive meningococcal meningitis B in adolescents and young adults between ten and 25 years.

TRUSELTIQ™ (infigratinib) for the Treatment of Cholangiocarcinoma

TRUSELTIQ™ (infigratinib) is an oral kinase inhibitor indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor II (FGFR2) fusion in adult patients.

Truvada – Antiretroviral Treatment to Prevent HIV

Truvada (emtricitabine and tenofovir disoproxil fumarate) is an antiretroviral indicated for preventing or reducing the risk of acquiring HIV-1.

Truxima (rituximab) for the Treatment of Cancer

ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well as granulomatosis with polyangiitis and microscopic polyangiitis.

Tudorza™ Pressair™ (aclidinium bromide inhalation powder) for Long-term Treatment of COPD

Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic drug indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It was developed by Forest Laboratories in collaboration with Spanish company Almirall.

TUKYSA™ (tucatinib) for the treatment of HER2-Positive Breast Cancer

TUKYSA™ (tucatinib) is the first HER-2 tyrosine kinase inhibitor approved in combination with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer.

Tygacil – Broad-Spectrum Antibiotic for Empiric

Developed by Wyeth Pharmaceuticals, Tygacil (tigecycline) is the first in a new class of antibiotics, the glycylcyclines

Tykerb – Dual Tyrosine Kinase Inhibitor

Tykerb (lapatinib ditosylate) is an epidermal growth factor receptor (EGFR) and ErbB-2 (Her2/neu) dual tyrosine kinase i

Tyrvaya (varenicline) for the Treatment of Dry Eye Disease

Tyrvaya (varenicline) is the first and only nasal spray approved by the FDA for the treatment of dry eye disease.

Tysabri – Therapeutic Monoclonal Antibody (Mab) for the Treatment of Multiple Sclerosis

The product of a joint development programme between by Elan Pharmaceuticals and Biogen, Tysabri (natalizumab) is a huma

U

Uceris (Budesonide) for Treating Ulcerative Colitis

Uceris (budesonide) is glucocorticoid receptor that is indicated for the treatment of ulcerative colitis. It is developed by US-based biopharmaceutical company Santarus, in collaboration with Cosmo Technologies.

UKONIQ™ (umbralisib) for the Treatment of Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)

UKONIQ™ (umbralisib) is the first and only oral, dual inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon, indicated for the treatment of previously treated relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL) in adult patients.

Ultomiris (ravulizumab-cwvz) for Paroxysmal Nocturnal Haemoglobinuria

Ultomiris™ (ravulizumab-cwvz) is a complement inhibitor drug approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults.

Ultresa – Treatment for Exocrine Pancreatic Insufficiency (EPI)

Aptalis Pharma's Ultresa is indicated for the treatment of exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis or other conditions. It was approved by the US Food and Drug Administration.

Ustekinumab, Treatment for Plaque Psoriasis by Centocor and Janssen-Cilag

Ustekinumab (CNTO 1275), a human anti-interleukin 12 (IL-12) and anti-interleukin 23 (IL-23) monoclonal antibody (MAb),

V

V1512 (melevodopa/carbidopa) for the Treatment of Parkinson’s Disease, Italy

V1512 (melevodopa/carbidopa) is an effervescent tablet formulation for the treatment of Parkinson's disease.

Vabysmo (faricimab-svoa) for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema

Vabysmo™ (faricimab-svoa) is the first injectable eye medicine approved for two conditions, nAMD and DME, simultaneously.

Valtorcitabine – Combination Drug Therapy for Chronic Hepatitis B

In partnership with Novartis Pharma, Idenix Pharmaceuticals is developing valtorcitabine (L-deoxycytidine) as part of a

VANFLYTA (quizartinib) for the Treatment of Acute Myeloid Leukaemia, USA

VANFLYTA® (quizartinib) is the first and only FLT3 inhibitor indicated to treat newly diagnosed acute myeloid leukaemia.